nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT02242071 | Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis | PHASE1 | WITHDRAWN | INTERVENTIONAL | false | Neurogen Brain and Spine Institute | The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients. | [
{
"type": "BIOLOGICAL",
"name": "Stem Cell"
}
] | 2008-12 | https://clinicaltrials.gov/study/NCT02242071 | [] | [
{
"facility": "Neurogen brain and spine institute",
"city": "Navi Mumbai",
"state": "Maharashtra",
"country": "India",
"status": "",
"lat": 19.03681,
"lon": 73.01582
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients with the diagnosis of definite Motor Neuron Disease/amyotrophic lateral sclerosis.\n* Age 18-80 years\n\nExclusion Criteria:\n\n* HIV/HBV/HCV\n* Malignancies\n* Bleeding tendencies\n* Pneumonia\n* Renal failure\n* Severe liver dysfunction\n* Severe anemia \\[hb \\< 8\\... | {
"compound": "autologous bone marrow mononuclear cells",
"targeting_mechanism": "stem cells that differentiate into support cells such as astrocytes, oligodendrocytes or microglia to provide trophic support, growth factors, anti-inflammatory cytokines, and glutamate buffering to degenerating motor neurons",
"tar... | ||
NCT06598202 | Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Xuanwu Hospital, Beijing | This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis. | [
{
"type": "DRUG",
"name": "exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop"
},
{
"type": "DRUG",
"name": "a placebo of exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop"
}
] | 2024-12-01 | https://clinicaltrials.gov/study/NCT06598202 | [] | [
{
"facility": "Xuanwu Hospital ,Capital Medical University",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
}
] | 010 8319 8277 | haojunwei@vip.163.com | {
"criteria": "Inclusion Criteria:\n\n* Age: 18-80 years, inclusion of both genders;\n* Disease duration: ≥6 months and ≤2 years (counted from the onset of any ALS symptoms);\n* Subjects must meet the El Escorial revised criteria (2000) for the diagnosis of ALS, with a diagnosis of Definite ALS, Probable ALS, Probabl... | {
"compound": "exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001)",
"targeting_mechanism": "small extracellular vesicles derived from mesenchymal stem cells that modulate neuroinflammation and provide neuroprotective effects through delivery of bioactive molecules including mi... |
NCT06658977 | RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial | PHASE3 | TERMINATED | INTERVENTIONAL | false | Macquarie University, Australia | Triumeq is an approved medicine for HIV. The effectiveness of Triumeq in Amyotrophic Lateral Sclerosis (ALS) is being investigated in the Lighthouse II trial. This study aims to assess whether Triumeq is safe and effective at delaying ALS disease progression when given long term. It is available for participants who ha... | [
{
"type": "DRUG",
"name": "Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)"
}
] | 2024-11-15 | https://clinicaltrials.gov/study/NCT06658977 | [
"Reverse transcriptase"
] | [
{
"facility": "Macquarie University, Neurology",
"city": "North Ryde",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.79677,
"lon": 151.12436
},
{
"facility": "Neuroscience Research Australia (NeuRA)",
"city": "Randwick",
"state": "New South ... | {
"criteria": "Inclusion Criteria:\n\n* Participants diagnosed with ALS according to the Lighthouse II protocol who completed the Lighthouse II trial.\n* Participants taking Riluzole must be on a stable dose.\n* Participants taking taurursodiol supplements (TUDCA) can participate in this trial if the supplement does ... | {
"compound": "Triumeq (abacavir 600mg, lamivudine 300mg, dolutegravir 50mg)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07257302 | Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis | NA | RECRUITING | INTERVENTIONAL | false | National Center of Neurology and Psychiatry, Japan | The goal of this clinical trial is to determine whether lung insufflation capacity (LIC) training can help maintain respiratory function and prolong tracheostomy-free survival in people with amyotrophic lateral sclerosis (ALS).
The main questions are:
Does early and continuous LIC training slow the decline in forced ... | [
{
"type": "DEVICE",
"name": "LIC Trainer (Lung Insufflation Capacity Trainer)"
}
] | 2025-11-01 | https://clinicaltrials.gov/study/NCT07257302 | [] | [
{
"facility": "National Center of Neurology and Psychiatry (NCNP)",
"city": "Kodaira",
"state": "Tokyo",
"country": "Japan",
"status": "RECRUITING",
"lat": 35.72603,
"lon": 139.48508
}
] | +81-42-341-2712 | rinri-jimu@ncnp.go.jp | {
"criteria": "Inclusion Criteria:\n\n* Age 20 years or older\n* Diagnosis of amyotrophic lateral sclerosis (ALS) according to the El Escorial or Awaji criteria\n* Not using noninvasive ventilation (NIV) and without tracheostomy at the start of LIC training\n* Able to perform study assessments and provide written inf... | {
"compound": "LIC Trainer (Lung Insufflation Capacity Trainer)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT03491462 | Arimoclomol in Amyotropic Lateral Sclerosis | PHASE3 | COMPLETED | INTERVENTIONAL | false | ZevraDenmark | A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS) | [
{
"type": "DRUG",
"name": "Arimoclomol"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2018-07-31 | https://clinicaltrials.gov/study/NCT03491462 | [
"heat_shock_protein"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
... | {
"criteria": "Inclusion Criteria:\n\n* Subject meets revised El Escorial criteria for clinically possible, clinically probable / clinically probable ALS laboratory-supported, clinically definite ALS or clinically definite familial ALS laboratory-supported\n* 18 months or less since first appearance of weakness (e.g.... | {
"compound": "arimoclomol",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03237741 | Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants | PHASE1 | COMPLETED | INTERVENTIONAL | false | Genentech, Inc. | This study will evaluate the pharmacokinetics and safety of GDC-0134 in healthy female volunteers of non-childbearing potential. The first part of the study will compare the bioavailability of a prototype capsule of GDC-0134 relative to an existing GDC-0134 reference capsule (Periods 1 and 2). The second part of the st... | [
{
"type": "DRUG",
"name": "Reference capsule GDC-0134"
},
{
"type": "DRUG",
"name": "Prototype capsule GDC-0134"
},
{
"type": "DRUG",
"name": "rabeprazole"
}
] | 2017-08-07 | https://clinicaltrials.gov/study/NCT03237741 | [] | [
{
"facility": "Quotient Clinical Ltd, Clinical Research Unit",
"city": "Nottingham",
"state": "",
"country": "United Kingdom",
"status": "",
"lat": 52.9536,
"lon": -1.15047
}
] | {
"criteria": "Inclusion Criteria:\n\n* Healthy female participants between 30 and 65 years of age, inclusive;\n* Within body mass index range 18.0 to 35.0 kilograms per square meter (kg/m\\^2), inclusive;\n* Female participants will be of non-childbearing potential;\n* In good health, determined by no clinically sig... | {
"compound": "GDC-0134",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01154283 | Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients | NA | COMPLETED | INTERVENTIONAL | false | Kirsten Gruis | The purpose of the study is to test whether noninvasive positive pressure ventilation (NIPPV) without expiratory positive airway pressure (EPAP) (inspiratory positive airway pressure (IPAP)-only) will result in an increase in patient usage of NIPPV compared with standard, Bi-level NIPPV. Secondarily, the investigators ... | [
{
"type": "DEVICE",
"name": "Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)"
}
] | 2008-01 | https://clinicaltrials.gov/study/NCT01154283 | [] | [
{
"facility": "University of Michigan",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Age greater than 18 years\n2. Definite or probable ALS by El Escorial criteria\n3. Maximal inspiratory force \\< 60 cm/H2O or FVC \\<50% predicted (American College of Chest Physicians' criteria for initiating NIPPV)\n4. Patients must have used NIPPV (typically administered as... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04172792 | Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Albert Christian Ludolph, Prof. | The LIPCAL-ALS study (NCT02306590) has provided preliminary evidence that a high-caloric nutrition might prolong survival in fast-progressing ALS patients. Since increasing the amount of calories of the intervention might possibly increase the beneficial effect, the investigators seek to investigate whether an ultra-hi... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "high-caloric fatty diet"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "ultra-high-caloric fatty diet"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "ultra-high-caloric carbohydrate-rich diet"
}
] | 2019-11-26 | https://clinicaltrials.gov/study/NCT04172792 | [] | [
{
"facility": "University of Ulm, Department of Neurology",
"city": "Ulm",
"state": "Baden-Wurttemberg",
"country": "Germany",
"status": "",
"lat": 48.39841,
"lon": 9.99155
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of Amyotrophic Lateral Sclerosis (ALS) according to the revised version of the El Escorial criteria (Ludolph et al. 2015)\n* Slope of ALS Functional Rating Scale Revised (ALSFRS-R) of \\>0.25 points per month at baseline visit based on the formula (48 - score at basel... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03127267 | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | PHASE3 | RECRUITING | INTERVENTIONAL | false | AB Science | The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Masitinib (6.0)"
},
{
"type": "DRUG",
"name": "Riluzole"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Masitinib (4.5)"
}
] | 2021-02-02 | https://clinicaltrials.gov/study/NCT03127267 | [
"C-KIT",
"PDGFRA"
] | [
{
"facility": "University of Alabama at Birmingham",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "RECRUITING",
"lat": 33.52066,
"lon": -86.80249
},
{
"facility": "University of Southern California",
"city": "Los Angeles",
"state": "Cali... | +33(0)147200014 | clinical@ab-science.com | {
"criteria": "Main inclusion criteria include:\n\n* Patients diagnosed with laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria\n* Patient with a familial or sporadic ALS\n* ALS disease duration from diagnosis no longer than 2... | {
"compound": "Masitinib",
"targeting_mechanism": "Tyrosine kinase inhibition that abrogates neuroinflammation and controls microgliosis in ALS.",
"targeting_mechanism_pmid": "27400786",
"animal_results": "Masitinib significantly prolonged survival and controlled microgliosis, neuroinflammation, and emergence o... |
NCT05003167 | Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS | NA | COMPLETED | INTERVENTIONAL | false | Purdue University | A tele-health treatment study for individuals with early stage ALS with the aim to improve communication, cough response, and respiratory strength. All participants complete a respiratory strength training program using an Expiratory Muscle Strength Training (EMST 150) device from the comfort of their homes for 6 weeks... | [
{
"type": "DEVICE",
"name": "Expiratory Muscle Strength Training (EMST-150)"
}
] | 2021-01-01 | https://clinicaltrials.gov/study/NCT05003167 | [] | [
{
"facility": "Purdue University",
"city": "West Lafayette",
"state": "Indiana",
"country": "United States",
"status": "",
"lat": 40.42587,
"lon": -86.90807
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of ALS\n* Within the early stages of disease progression (i.e., able to talk, breathe, and eat independently)\n* Speaker of English\n* Have a family member/caregiver willing to assist as needed\n* Have access to an electronic device and internet for tele-health\n\nExc... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05349721 | Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS | PHASE2 | TERMINATED | INTERVENTIONAL | false | PTC Therapeutics | This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS. | [
{
"type": "DRUG",
"name": "PTC857"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2022-05-15 | https://clinicaltrials.gov/study/NCT05349721 | [
"HSPA4"
] | [
{
"facility": "UC Irvine Health ALS and Neuromuscular Center",
"city": "Orange",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.78779,
"lon": -117.85311
},
{
"facility": "Forbes Norris MDA/ALS Research Center at California Pacific Medical Center",
... | {
"criteria": "Key Inclusion Criteria:\n\n* ALS with preserved function, defined as:\n\n 1. Onset of the first symptom leading to the diagnosis of ALS ≤24 months at the time of the initial Screening Visit\n 2. Revised EL Escorial criteria of either:\n\n (i) Clinically definite ALS (ii) Clinically probable ALS\n* A... | {
"compound": "PTC857",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01811355 | Mexiletine for the Treatment of Muscle Cramps in ALS | PHASE4 | COMPLETED | INTERVENTIONAL | false | Bjorn Oskarsson, MD | The purpose of this study is to determine if mexiletine is effective for the treatment of muscle cramps in Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Mexiletine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2013-05 | https://clinicaltrials.gov/study/NCT01811355 | [
"Voltage-gated sodium channel"
] | [
{
"facility": "UCD Telehealth Network - Lake Almanor Clinic",
"city": "Chester",
"state": "California",
"country": "United States",
"status": "",
"lat": 40.30627,
"lon": -121.23191
},
{
"facility": "UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program",
"city": ... | {
"criteria": "Inclusion Criteria:\n\n* ALS diagnosed according to El Escorial criteria (Awaji version) as: Possible, Probable, or Definite.\n* Experiencing cramps as a moderate or severe symptom as defined by willingness to take a medication for the symptom\n* ≥2 cramps per week during run in week\n* Life expectancy... | {
"compound": "Mexiletine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02682030 | The Use of Airway Clearance Devices in ALS | NA | COMPLETED | INTERVENTIONAL | false | Cedars-Sinai Medical Center | The investigator is examining the use of one airway clearance medical device compared to the use of two airway clearance medical devices together in patients with amyotrophic lateral sclerosis (ALS). More specifically, the investigator wants to know how effective the use of either a mechanical High Frequency Chest Comp... | [
{
"type": "DEVICE",
"name": "High Frequency Chest Compression Device (HFCC)"
},
{
"type": "DEVICE",
"name": "Cough Assist"
}
] | 2016-03 | https://clinicaltrials.gov/study/NCT02682030 | [] | [
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Suspected, possible, probable, Probable (Lab-Supported), or Definite ALS according to El Escorial Criteria\n2. Males and females age 18 and above\n3. Novel to airway clearance device use\n4. Forced vital capacity ≤ 75% of predicted\n\nExclusion Criteria:\n\n1. Any contraindica... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01277315 | Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Charite University, Berlin, Germany | Amyotrophic Lateral Sclerosis (ALS) is an adult neurodegenerative disease that is caused by a selective degeneration of the motor nerve cells in the cortex and myelon. As a result of motor neurodegeneration, a progredient paralysis of the extremities and of the speaking, swallowing, and breathing musculature develops. ... | [
{
"type": "DRUG",
"name": "Anakinra"
}
] | 2011-02 | https://clinicaltrials.gov/study/NCT01277315 | [
"IL-1",
"neuroinflammation"
] | [
{
"facility": "Charité University Hospital",
"city": "Berlin",
"state": "",
"country": "Germany",
"status": "",
"lat": 52.52437,
"lon": 13.41053
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients between 18 and 80 years of age\n* Clinical diagnosis of amyotrophic lateral sclerosis with predominant affection of the lower motor neuron or the clinical ALS variant of progressive muscular atrophy (PMA)\n* Clinical signs of lower motor neuron degeneration in at least... | {
"compound": "Anakinra",
"targeting_mechanism": "IL-1 receptor antagonist that reduces neuroinflammation",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03367650 | Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies | NA | UNKNOWN | INTERVENTIONAL | false | Centre Hospitalier Universitaire de la Guadeloupe | The diagnosis and the follow-up of the patients reached of SLA is centralized, since a few years, at the the Caribbean Reference center of the rare neurological diseases (CERCA labélisé in 2006) in Martinique and at the Unity of coverage of the neuromuscular Diseases, SLA and the rare neurological diseases (create in 2... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Blood sample and environmental survey"
}
] | 2014-05-13 | https://clinicaltrials.gov/study/NCT03367650 | [] | [
{
"facility": "Hospital University Center of Pointe-à-Pitre",
"city": "Pointe-à-Pitre",
"state": "",
"country": "Guadeloupe",
"status": "RECRUITING",
"lat": 16.23638,
"lon": -61.53459
},
{
"facility": "Hospital University Center of Martinique",
"city": "Fort-de-France",
"... | 0590 93 46 86 | chantal.lerus@chu-guadeloupe.fr | {
"criteria": "Inclusion Criteria:\n\n* Patient or third-party responsible for receiving information on the study and who signed informed consent ;\n* Patient age over 18 years;\n* Patient living in the Antilles;\n* Patient with ALS or SLP (primary lateral sclerosis, pure central form of ALS).\n\nExclusion Criteria:\... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04889248 | Inspiratory Muscle Training With Powerbreath Device in Patients With ALS | NA | COMPLETED | INTERVENTIONAL | false | Universidad Francisco de Vitoria | Abstract:
Context/background: people affected by Amyotrophic Lateral Sclerosis (ALS) see their own life totally disturbed after the diagnosis. This disease also courses, apart from the functional and depressing worsening, with internal damage manifested by a cardio respiratory deterioration. There are not many clinica... | [
{
"type": "OTHER",
"name": "Inspiratory Muscle Training with Powerbreath IMT device."
}
] | 2021-05-17 | https://clinicaltrials.gov/study/NCT04889248 | [] | [
{
"facility": "Universidad Francisco de Vitoria",
"city": "Pozuelo de Alarcón",
"state": "Madrid",
"country": "Spain",
"status": "",
"lat": 40.43293,
"lon": -3.81338
}
] | {
"criteria": "Inclusion Criteria:\n\n\\- Subjects with ALS\n\nExclusion Criteria:\n\n* PImax more than 30mmH2O\n* Score higher than 2 in GDS Reisberg scale\n* Using already respiratory devices during the day (except night CPAPs support) more than 14h/day.\n* Unstable medical disease for the last 3 years.\n* Use of I... | {
"compound": "unknown",
"targeting_mechanism": "Inspiratory muscle training to strengthen respiratory muscles and counteract cardiorespiratory deterioration in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_f... | ||
NCT06765499 | The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease | NA | RECRUITING | INTERVENTIONAL | false | First People's Hospital of Hangzhou | Motor Neuron Disease (MND) is the result of dysfunction of the upper motor neurons in the precentral gyrus of the frontal lobe or the lower motor neurons in the ventral horn of the spinal cord. Amyotrophic lateral sclerosis (ALS) is the most common, disabling, and fatal motor neuron disease in adults. Sarcopenia is a s... | [
{
"type": "OTHER",
"name": "Chinese medicine - Silkworm pupa powder"
},
{
"type": "OTHER",
"name": "Ultra-low dose silkworm pupa powder"
}
] | 2025-03-04 | https://clinicaltrials.gov/study/NCT06765499 | [
"sarcopenia"
] | [
{
"facility": "Hangzhou First People's Hospital",
"city": "Hangzhou",
"state": "Zhejiang",
"country": "China",
"status": "RECRUITING",
"lat": 30.29365,
"lon": 120.16142
}
] | 0571-56007429 | 757318708@qq.com | {
"criteria": "Inclusion Criteria:\n\n* Voluntarily participate in the clinical study, fully understand and be informed about the study, and sign the Informed Consent Form (ICF); willing to follow and capable of completing all trial procedures.\n* Gender is not limited, age at the time of signing ICF: ≥18 years old, ... | {
"compound": "Silkworm pupa powder",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06165172 | Early Feasibility Study of the MyoRegulator® for Treatment of ALS | NA | COMPLETED | INTERVENTIONAL | false | PathMaker Neurosystems Inc. | This is a single-center, single-arm, open-label study aiming to assess the safety and feasibility of the MyoRegulator® device when used to treat individuals with amyotrophic lateral sclerosis (ALS). This study is the first use of the MyoRegulator® device to treat individuals with ALS. The main objective of this study i... | [
{
"type": "DEVICE",
"name": "MyoRegulator®"
}
] | 2023-06-21 | https://clinicaltrials.gov/study/NCT06165172 | [] | [
{
"facility": "Spaulding Rehabilitation Hospital",
"city": "Charlestown",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.37787,
"lon": -71.062
}
] | {
"criteria": "Inclusion Criteria:\n\n* 18 years of age or older\n* A clinical diagnosis of ALS as confirmed by medical history\n* Willing to forgo botulinum toxin, phenol or alcohol injections, intrathecal baclofen, digitalis, and morphine for the study duration\n* Willing to refrain from participation in any other ... | {
"compound": "MyoRegulator®",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03548311 | Clinical Trial of Ultra-high Dose Methylcobalamin for ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Eisai Co., Ltd. | To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by Updated Awaji Criteria within 12 months after the clinical onset. First they are followed ... | [
{
"type": "DRUG",
"name": "methylcobalamin"
},
{
"type": "DRUG",
"name": "saline solution"
}
] | 2017-11-01 | https://clinicaltrials.gov/study/NCT03548311 | [
"mitochondrial_function"
] | [
{
"facility": "Nagoya University Hospital",
"city": "Nagoya",
"state": "Aichi-ken",
"country": "Japan",
"status": "",
"lat": 35.18147,
"lon": 136.90641
},
{
"facility": "Miyoshi Neurological Clinic",
"city": "Miyoshi",
"state": "Hiroshima",
"country": "Japan",
"st... | {
"criteria": "Inclusion Criteria:\n\nTreatment and OLE Phase:\n\n* ALS patients within 12 months after clinical onset at the entry\n* Diagnosed based on updated Awaji criteria: definite, probably or laboratory supported probable\n* Decline of ALSFRSR being 1 or 2 during observation period of 12 weeks\n* Japanese Cli... | {
"compound": "methylcobalamin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05837507 | Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange | NA | TERMINATED | INTERVENTIONAL | false | University Hospital, Montpellier | The median survival of patients with amyotrophic lateral sclerosis (ALS) is 3 to 5 years and mortality is mainly related to respiratory failure. Non-invasive ventilation (NIV) and multidisciplinary management improve the quality of life and survival of patients. However, patients have mobility difficulties related to t... | [
{
"type": "OTHER",
"name": "Telerehabilitation solution (m-Rehab)"
},
{
"type": "OTHER",
"name": "Usual management including NIV."
}
] | 2023-07-05 | https://clinicaltrials.gov/study/NCT05837507 | [] | [
{
"facility": "Uh Montpellier",
"city": "Montpellier",
"state": "Montpellier",
"country": "France",
"status": "",
"lat": 43.61093,
"lon": 3.87635
},
{
"facility": "Clinique du Millénaire",
"city": "Montpellier",
"state": "",
"country": "France",
"status": "",
... | {
"criteria": "Inclusion Criteria:\n\n* Patients between 30 and 85 years old\n* Diagnosis of ALS\n* Indication and acceptance of non-invasive ventilation\n* Patient equipped with suitable equipment (tablet, computer, telephone, etc.) with an internet connection at home\n* Patient able to read and understand the proce... | {
"compound": "unknown",
"targeting_mechanism": "Telerehabilitation platform with telemonitoring to support non-invasive ventilation management and multidisciplinary care in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
... | ||
NCT06671236 | Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases | PHASE1 | RECRUITING | INTERVENTIONAL | false | Novabio Therapeutics | An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS). | [
{
"type": "BIOLOGICAL",
"name": "Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)"
}
] | 2024-11-21 | https://clinicaltrials.gov/study/NCT06671236 | [
"neuroinflammation"
] | [
{
"facility": "The First Affiliated Hospital of Zhengzhou University",
"city": "Zhengzhou",
"state": "Henan",
"country": "China",
"status": "RECRUITING",
"lat": 34.75778,
"lon": 113.64861
}
] | 609-716-7786; +86 15800843507 | lumingqi@novabiotx.com | {
"criteria": "Inclusion Criteria:\n\n\\-\n\nPatients must meet all of the following criteria to be eligible for enrollment in this study:\n\n1. Male or female patients aged 18 to 70 years;\n2. According to current international diagnostic criteria:\n\n ALS: defined by the Gold Coast Diagnostic Criteria (Shefner, 2... | {
"compound": "Autologous Human Polyclonal Regulatory T Cells (NP001 Cell Injection)",
"targeting_mechanism": "Modulation of neuroinflammation through adoptive transfer of regulatory T cells to suppress CNS inflammation in ALS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_res... |
NCT02290886 | A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "OTHER",
"name": "Intravenous administration of placebo"
},
{
"type": "DRUG",
"name": "Intravenous administration of 1 million of MSC"
},
{
"type": "DRUG",
"name": "Intravenous administration of 2 million of MSC"
},
{
"type": "DRUG",
"name": "Intravenous adminis... | 2014-07 | https://clinicaltrials.gov/study/NCT02290886 | [
"neuroinflammation"
] | [
{
"facility": "Hospital Regional Universitario Reina Sofía",
"city": "Córdoba",
"state": "",
"country": "Spain",
"status": "",
"lat": 37.89155,
"lon": -4.77275
},
{
"facility": "Hospital Regional Universitario de Málaga",
"city": "Málaga",
"state": "",
"country": "Spa... | {
"criteria": "Inclusion Criteria:\n\n1. Women and males over 18-year-old.\n2. Good understanding of the protocol and aptitude to grant the informed assent.\n3. Diagnosis of sporadic ALS, with diagnosis of certainty, that is to say, definite or probable, in agreement with the criteria of \"El Escorial\", of the World... | {
"compound": "Autologous Mesenchymal Stem Cells (MSC) from adipose tissue",
"targeting_mechanism": "Reduction of neuroinflammation through cell therapy to address inflammation-driven neurodegeneration in ALS.",
"targeting_mechanism_pmid": "37433768",
"animal_results": "unknown",
"animal_results_pmid": "",
... | ||
NCT06992596 | UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices | NA | RECRUITING | INTERVENTIONAL | false | Neuralink Corp | The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions.
The N1 Implant is a wireless, rechargeable device ... | [
{
"type": "DEVICE",
"name": "N1 Implant"
},
{
"type": "DEVICE",
"name": "R1 Robot"
}
] | 2025-05-09 | https://clinicaltrials.gov/study/NCT06992596 | [] | [
{
"facility": "Cleveland Clinic Abu Dhabi (CCAD)",
"city": "Abu Dhabi",
"state": "",
"country": "United Arab Emirates",
"status": "RECRUITING",
"lat": 24.45118,
"lon": 54.39696
}
] | (877) 398-4465 | clinical-team-ct@neuralink.com | {
"criteria": "Inclusion Criteria:\n\n* (a) A diagnosis of a spinal cord injury (\\>12 months), stroke (\\>12 months), or other neurological condition causing the participant to experience bilateral upper limb motor impairment, with no expectation of recovery.\n\nOR (b) A diagnosis of Amyotrophic Lateral Sclerosis (A... | {
"compound": "N1 Implant and R1 Robot (Brain-Computer Interface)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT03567213 | Investigation on the Cortical Communication (CortiCom) System | NA | RECRUITING | INTERVENTIONAL | false | Johns Hopkins University | The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In eac... | [
{
"type": "DEVICE",
"name": "Surgical implantation of CortiCom system"
}
] | 2021-12-14 | https://clinicaltrials.gov/study/NCT03567213 | [] | [
{
"facility": "Johns Hopkins Medicine",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "RECRUITING",
"lat": 39.29038,
"lon": -76.61219
}
] | 410-955-6772 | ncrone@jhmi.edu | {
"criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of tetraplegia (quadriplegia), brainstem stroke , amyotrophic lateral sclerosis (ALS) or Locked-in Syndrome (LIS)\n* Tetraplegia diagnosis, ALS diagnosis, stroke, or LIS etiology onset occurred at least one year prior to enrollment\n* Complete or incomplete t... | {
"compound": "CortiCom system (platinum PMT subdural cortical electrode grids)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | PHASE3 | COMPLETED | INTERVENTIONAL | false | Biogen | The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker ... | [
{
"type": "DRUG",
"name": "Tofersen"
}
] | 2017-03-08 | https://clinicaltrials.gov/study/NCT03070119 | [
"SOD1"
] | [
{
"facility": "Research Site",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Research Site",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": ""... | {
"criteria": "Key Inclusion Criteria:\n\n* Must have diagnosis of superoxide dismutase 1-amyotrophic lateral sclerosis (SOD1-ALS), and must have completed the End of Study Visit for either Parts A, B, or C of Study 233AS101 (NCT02623699) (i.e., were not withdrawn).\n* If taking riluzole, participant must be receivin... | {
"compound": "Tofersen (BIIB067)",
"targeting_mechanism": "Antisense oligonucleotide that reduces mutant SOD1 expression to slow motor neuron degeneration.",
"targeting_mechanism_pmid": "37975798",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_fr... | ||
NCT04882904 | Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. | NA | RECRUITING | INTERVENTIONAL | false | Centre Hospitalier Universitaire de Liege | ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.
The investigators have planned to assess patient every three months for a year. On each visit, participants will un... | [
{
"type": "DEVICE",
"name": "Actimyo°"
}
] | 2020-09-25 | https://clinicaltrials.gov/study/NCT04882904 | [] | [
{
"facility": "CHR Citadelle",
"city": "Liège",
"state": "Liège",
"country": "Belgium",
"status": "RECRUITING",
"lat": 50.63373,
"lon": 5.56749
}
] | 43218222 | Laurie.Medard@citadelle.be | {
"criteria": "Inclusion Criteria:\n\n* Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.\n* Over 18 years old.\n* Signed informed consent\n* If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT00931944 | Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS. | [
{
"type": "DRUG",
"name": "KNS-760704"
}
] | 2009-07 | https://clinicaltrials.gov/study/NCT00931944 | [
"potassium_channels"
] | [
{
"facility": "University of Arkansas for Medical Sciences",
"city": "Little Rock",
"state": "Arkansas",
"country": "United States",
"status": "",
"lat": 34.74648,
"lon": -92.28959
},
{
"facility": "UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center",
"city": "Los A... | {
"criteria": "Inclusion Criteria:\n\n1. Patient has provided signed informed consent for this trial before the commencement of any study-related procedure\n2. Patient is actively participating in Knopp Protocol KNS-760704-CL201 and has completed the Part 2 Week 28 visit in that study or patient is actively receiving... | {
"compound": "KNS-760704",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02492516 | Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | Royan Institute | Amyotrophic lateral sclerosis (ALS) is a lethal degenerative disorder that upper motor and lower motor neurons are destroyed in brain stem and spinal cord. Riluzole is the only therapeutic option now. Recently several studies have shown that stem cell transplantation is safe and can be effective in reduction of disease... | [
{
"type": "BIOLOGICAL",
"name": "mesenchymal stem cells"
}
] | 2014-09 | https://clinicaltrials.gov/study/NCT02492516 | [
"neuroinflammation"
] | [
{
"facility": "Royan Institute",
"city": "Tehran",
"state": "",
"country": "Iran",
"status": "",
"lat": 35.69439,
"lon": 51.42151
}
] | {
"criteria": "Inclusion Criteria:\n\n* Both gender\n* Age: 18-55\n* Sporadic form of disease\n* ALS-FRS\\> = 24\n* FVC \\>= 40%\n\nExclusion Criteria:\n\n* Familial form of ALS\n* Malignancy\n* Autoimmune disease\n* Diagnosis of other motor neuron diseases",
"sex": "ALL",
"min_age": "18 Years",
"max_age": "55 ... | {
"compound": "mesenchymal stem cells",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT02917681 | Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | UNKNOWN | INTERVENTIONAL | false | University of Sao Paulo General Hospital | The study aims to evaluate primarily safety of two injections of autologous mesenchymal stem cells in Amyotrophic Lateral Sclerosis patients. Secondary outcomes of efficacy will also be evaluated | [
{
"type": "OTHER",
"name": "Two intrathecal MSC injections"
}
] | 2016-09 | https://clinicaltrials.gov/study/NCT02917681 | [
"neuroinflammation"
] | [
{
"facility": "University of Sao Paulo School of Medicine Clinics Hospital",
"city": "São Paulo",
"state": "São Paulo",
"country": "Brazil",
"status": "RECRUITING",
"lat": -23.5475,
"lon": -46.63611
}
] | 551130617460 | contato@projetoelabrasil.com.br | {
"criteria": "Inclusion Criteria:\n\n1. Age between 18 and 70\n2. Possible, probable or definite ALS following El Escorial Revised Criteria (Brooks, 2000)\n3. ALSFRS-r ≥30 at enrollment\n4. Forced Vital Capacity ≥65% of the height and weight standard\n5. No-pregnancy agreement\n6. Regional accessibility to the study... | {
"compound": "autologous mesenchymal stem cells",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Bone marrow-derived mesenchymal stem cells have shown potential in several ALS rodent models with varying delivery methods, cell amounts, timing of intervention, and differenti... |
NCT03645031 | Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease | NA | COMPLETED | INTERVENTIONAL | false | University of Florida | This project seeks to investigate the effects of a single acute intermittent hypoxia (AIH) session on respiratory and non-respiratory motor function and EMG (electromyography) activity on patients with ALS (amyotrophic lateral sclerosis) and healthy controls. | [
{
"type": "OTHER",
"name": "Acute Intermittent Hypoxia"
},
{
"type": "OTHER",
"name": "Sham Acute Intermittent Hypoxia"
}
] | 2018-10-01 | https://clinicaltrials.gov/study/NCT03645031 | [
"hypoxia_signaling"
] | [
{
"facility": "UF Clinical Research Center",
"city": "Gainesville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 29.65163,
"lon": -82.32483
},
{
"facility": "University of Florida",
"city": "Gainesville",
"state": "Florida",
"country": "United ... | {
"criteria": "Inclusion Criteria:\n\n* a healthy adult\n* clinical diagnosis of ALS\n* baseline FVC \\>60% predicted for age, sex and height.\n\nExclusion Criteria:\n\n* pregnant\n* diagnosed cardiovascular disease\n* a BMI \\>35 kg/m2\n* currently take selective serotonin reuptake inhibitors (SSRI)\n* history of se... | {
"compound": "Acute Intermittent Hypoxia",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07100119 | A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | PHASE1 | RECRUITING | INTERVENTIONAL | false | Eli Lilly and Company | The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the blood... | [
{
"type": "DRUG",
"name": "LY4256984"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2025-08-05 | https://clinicaltrials.gov/study/NCT07100119 | [
"C9orf72"
] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "RECRUITING",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Heritage Medical Research Clinic",
"city": "Calgary",
"state": "",
"country": "Canada",
"status": "NOT_YET_REC... | 1-317-615-4559 | LillyTrials@Lilly.com | {
"criteria": "Inclusion Criteria:\n\n* Have a definite, possible, or probable diagnosis of sporadic amyotrophic lateral sclerosis (ALS) made by a physician experienced with the management of ALS\n* ALS symptom onset as determined by the Investigator within 24 months of Screening\n* Have a body mass index (BMI) withi... | {
"compound": "LY4256984",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00868166 | Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Hoffmann-La Roche | The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month survival rate. | [
{
"type": "DRUG",
"name": "Olesoxime"
},
{
"type": "DRUG",
"name": "Placebo Comparator"
},
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2009-04-30 | https://clinicaltrials.gov/study/NCT00868166 | [
"mitochondrial_dysfunction"
] | [
{
"facility": "University Hospital Gasthuisberg - Dept Neurology - Herestraat 49",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et... | {
"criteria": "Inclusion Criteria:\n\n* Patients with sporadic or familial Amyotrophic Lateral Sclerosis\n* Patients with a clinical diagnosis of laboratory-supported probable, probable, or definite ALS according to the modified El Escorial criteria8.\n* Have signed an Informed Consent to participate to the trial bef... | {
"compound": "Olesoxime",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05744310 | Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families | NA | RECRUITING | INTERVENTIONAL | false | Haukeland University Hospital | Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years. The patient physical and psychological sufferings in ALS are immense, and apart from Riluzole, there is no effective treatment. Care of advanced ALS ... | [
{
"type": "DEVICE",
"name": "Long term mechanical ventilation support"
},
{
"type": "DEVICE",
"name": "No long term mechanical ventilation support"
}
] | 2023-04-21 | https://clinicaltrials.gov/study/NCT05744310 | [] | [
{
"facility": "Nordland Hospital Bodø",
"city": "Bodø",
"state": "Nordland",
"country": "Norway",
"status": "RECRUITING",
"lat": 67.28267,
"lon": 14.37513
},
{
"facility": "Sørlandet Hospital Trust",
"city": "Kristiansand",
"state": "Vest Agder",
"country": "Norway",
... | + 47 55975063 | ole-bjorn.tysnes@helse-bergen.no | {
"criteria": "Inclusion criteria for patients:\n\n1. A clinical diagnosis of probable ALS according to the revised El Escorial criteria\n2. Progression of the illness leading the consulting physician to offer treatment with LTMV\n3. Can communicate in Norwegian\n\nInclusion criteria for partners of ALS patients:\n\n... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT02710162 | Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS) | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | University of Florida | Individuals with th Amyotrophic Lateral Sclerosis are at high risk for swallowing impairment (dysphagia) which leads to malnutrition, decreased pulmonary health, aspiration and aspiration pneumonia. These sequelae necessitate timely identification of at risk individuals to ensure optimal management of oral intake and p... | [
{
"type": "DEVICE",
"name": "Micro Mouth Pressure Meter"
},
{
"type": "DEVICE",
"name": "Iowa Oral Performance Instrument"
},
{
"type": "DEVICE",
"name": "Electrical Impedance Myography"
},
{
"type": "DRUG",
"name": "Capsaicin"
},
{
"type": "PROCEDURE",
"name"... | 2016-04 | https://clinicaltrials.gov/study/NCT02710162 | [] | [
{
"facility": "University of Florida",
"city": "Gainesville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 29.65163,
"lon": -82.32483
}
] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of probable or definite ALS\n\nExclusion Criteria:\n\n* allergies to barium or capsaicin\n* tracheotomy or mechanical ventilation\n* absence of diaphragmatic pacer\n* respiratory disease (COPD).",
"sex": "ALL",
"min_age": "21 Years",
"max_age": "85 Years",
"he... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01285583 | Safety Extension Study of TRO19622 in ALS | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Hoffmann-La Roche | The purpose of the assay is to assess the safety of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, after completion of the preceding clinical trial (TRO19622 CL E Q 1015-1) in an open label extension. | [
{
"type": "DRUG",
"name": "TRO19622"
}
] | 2010-10 | https://clinicaltrials.gov/study/NCT01285583 | [
"mitochondrial_dysfunction"
] | [
{
"facility": "University Hospital Gasthuisberg - Dept Neurology - Herestraat 49",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et... | {
"criteria": "Inclusion Criteria:\n\n* Patients must have completed the 18-month safety and efficacy study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole (Protocol TRO19622 CL E Q 1015-1).\n* Both the investigator and the patient will decide based on previous good tolerance and oth... | {
"compound": "TRO19622",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07625605 | The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease | NA | COMPLETED | INTERVENTIONAL | false | The University of Tennessee, Knoxville | Brief summary template
The goal of this trial is to test the feasibility and efficacy of the Mediterranean-DASH Intervention for Neurodegenerative Delay (the MIND diet) in people living with amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD) and healthy controls. The main question\[s\] it aims to answer ... | [
{
"type": "BEHAVIORAL",
"name": "The MIND diet"
}
] | 2023-11-20 | https://clinicaltrials.gov/study/NCT07625605 | [] | [
{
"facility": "Gary E Shealy Memorial ALS Clinic",
"city": "Elizabethton",
"state": "Tennessee",
"country": "United States",
"status": "",
"lat": 36.34872,
"lon": -82.21069
},
{
"facility": "University Neurology",
"city": "Knoxville",
"state": "Tennessee",
"country": ... | {
"criteria": "Inclusion Criteria for Participants with ALS:\n\n* Meet the El Escorial Criteria for definite, probable, or possible ALS:\n\n * Definite ALS is defined as presence of upper motor neuron (UMN) and lower motor neuron (LMN) signs in the bulbar region and at 2 of the other spinal regions\n * Probable ALS... | {
"compound": "unknown",
"targeting_mechanism": "The MIND diet promotes neuroprotection through dietary pattern modification.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT02872142 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Grifols Therapeutics LLC | This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in participants with amyotrophic lateral sclerosis (ALS). | [
{
"type": "BIOLOGICAL",
"name": "Albutein 5%"
},
{
"type": "PROCEDURE",
"name": "Plasma Exchange"
}
] | 2016-08-29 | https://clinicaltrials.gov/study/NCT02872142 | [] | [
{
"facility": "Dartmouth-Hitchcock Medical Center",
"city": "Lebanon",
"state": "New Hampshire",
"country": "United States",
"status": "",
"lat": 43.64229,
"lon": -72.25176
}
] | {
"criteria": "Inclusion Criteria:\n\n* Signed informed consent\n* Subjects over 18 years of age and less than 70 years old\n* Subjects with a possible, probable-lab supported, probable, or definite diagnosis of Amyotrophic Lateral Sclerosis (ALS), according to the revised El Escorial criteria\n* Subjects having expe... | {
"compound": "Albutein 5% (human albumin)",
"targeting_mechanism": "Plasma exchange with albumin replacement aims to remove circulating pathogenic factors in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid"... | ||
NCT02987413 | Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients | PHASE1 | COMPLETED | INTERVENTIONAL | false | Hospital e Maternidade Dr. Christóvão da Gama | Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that selectively affects motor neurons in the brain and spinal cord, leading to bulbar, respiratory, and limb weakness. There is no effective treatment, and the disease usually progresses to death within 2 to 4 years. The therapeutic plastic... | [
{
"type": "BIOLOGICAL",
"name": "Autologous Mesenchymal stem cells (MSCs)"
}
] | 2015-04-28 | https://clinicaltrials.gov/study/NCT02987413 | [
"neuroinflammation"
] | [
{
"facility": "Hospital e Maternidade Dr Christovao da Gama",
"city": "Santo André",
"state": "São Paulo",
"country": "Brazil",
"status": "",
"lat": -23.66389,
"lon": -46.53833
},
{
"facility": "Instituto de Ensino e Pesquisas - IEP-São Lucas",
"city": "São Paulo",
"state... | {
"criteria": "Inclusion Criteria:\n\n* Women and males over 18-year-old.\n* Diagnosis of ALS in agreement with the criteria of \"EL SCORE\"\n* Less than 24 months of evolution of the disease (from the beginning of the symptoms).\n* Good understanding of the protocol and aptitude to grant the informed consent\n* Infe... | {
"compound": "Autologous Mesenchymal stem cells (MSCs)",
"targeting_mechanism": "Mesenchymal stem cells differentiate into supportive glial cells and secrete growth factors and anti-inflammatory cytokines to support degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"animal_results": "Bone m... | ||
NCT07213440 | Identification of Early Markers for ALS | NA | RECRUITING | INTERVENTIONAL | false | Institut National de la Santé Et de la Recherche Médicale, France | Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficac... | [
{
"type": "PROCEDURE",
"name": "lumbar puncture"
}
] | 2024-09-30 | https://clinicaltrials.gov/study/NCT07213440 | [] | [
{
"facility": "CHU Tours",
"city": "Tours",
"state": "France",
"country": "France",
"status": "RECRUITING",
"lat": 47.39484,
"lon": 0.70398
}
] | +33247473724 | philippe.corcia@univ-tours.fr | {
"criteria": "Inclusion Criteria:\n\nFIRST GROUP: Premotor gene mutation carriers (PGMC):\n\n* 18-90 years of age\n* Provision of a written informed consent\n* Affiliation with a social security scheme or beneficiary of such a scheme\n* Diagnosed by a clinically certified laboratory with a disease- causing mutation ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT00372879 | Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Muscular cramps are a common and uncomfortable symptom of amyotrophic lateral sclerosis (ALS). This clinical trial will compare the response of high dose vitamin E supplementation to placebo for treatment of muscular cramps in patients with ALS. We hypothesize that vitamin E will be more effective than placebo in treat... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Vitamin E"
}
] | 2006-12 | https://clinicaltrials.gov/study/NCT00372879 | [
"oxidative_stress"
] | [
{
"facility": "London Health Sciences Centre",
"city": "London",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 42.98339,
"lon": -81.23304
}
] | {
"criteria": "Inclusion Criteria:\n\n* Adults (\\> age 18 years)\n* Probable or definite ALS by El Escorial Revised criteria\n* At least 2 painful muscle cramps in one or more of the limbs per week.\n* May have tried other medications for cramping in the past.\n* If participants are currently on treatment for cramps... | {
"compound": "Vitamin E",
"targeting_mechanism": "Vitamin E functions as an antioxidant to reduce oxidative stress in ALS.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01378676 | A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Cytokinetics | The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days. | [
{
"type": "DRUG",
"name": "Placebo (Part A)"
},
{
"type": "DRUG",
"name": "CK-2017357 (Part A)"
},
{
"type": "DRUG",
"name": "CK-2017357 (Part A)"
},
{
"type": "DRUG",
"name": "CK-2017357 (Part A)"
},
{
"type": "DRUG",
"name": "Riluzole 50 MG (Part B)"
},
... | 2011-06 | https://clinicaltrials.gov/study/NCT01378676 | [
"muscle_contractility"
] | [
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Mayo Florida",
"city": "Jacksonville",
"state": "Florida",
"country": "Uni... | {
"criteria": "Key Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an Informed Consent Form (ICF)\n2. Males or females 18 years of age or older\n3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis o... | {
"compound": "CK-2017357",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06828523 | Assessing Perceptual Effects of Interactive Tasks | NA | RECRUITING | INTERVENTIONAL | false | Penn State University | In this study, we will evaluate how solo, naive listeners perceive the speech of people with amyotrophic lateral sclerosis (ALS) and age-matched speakers produced across interactive and non-interactive contexts with an unfamiliar, naive interlocutor. | [
{
"type": "BEHAVIORAL",
"name": "Listener judgements of speech produced in different tasks"
}
] | 2025-10-17 | https://clinicaltrials.gov/study/NCT06828523 | [] | [
{
"facility": "Speech Core, Pennsylvania State University",
"city": "University Park",
"state": "Pennsylvania",
"country": "United States",
"status": "RECRUITING",
"lat": 40.80201,
"lon": -77.85639
}
] | 814-867-3373 | ajo150@psu.edu | {
"criteria": "Inclusion Criteria:\n\n* passing the remote hearing screening\n* having no known speech, language or neurological disorders per self-report\n* being a native monolingual speaker of American English\n* having no experience communicating with people with dysarthria\n* being between the ages of 18 and 65.... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04615923 | HEALEY ALS Platform Trial - Regimen D Pridopidine | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS. | [
{
"type": "DRUG",
"name": "Pridopidine"
},
{
"type": "DRUG",
"name": "Matching Placebo"
}
] | 2020-12-18 | https://clinicaltrials.gov/study/NCT04615923 | [
"dopamine_d2_receptor_signaling"
] | [
{
"facility": "Healey Center for ALS at Mass General",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\nExclusion Criteria:\n\n* The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\n 1. ... | {
"compound": "Pridopidine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05178810 | Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis | PHASE3 | COMPLETED | INTERVENTIONAL | false | Ferrer Internacional S.A. | Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients. | [
{
"type": "DRUG",
"name": "FAB122"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-10-18 | https://clinicaltrials.gov/study/NCT05178810 | [
"oxidative_stress"
] | [
{
"facility": "University Hospitals Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "CHRU de Lille - Hôpital Roger Salengro",
"city": "Lille",
"state": "",
"country": "France",
"status": ... | {
"criteria": "Main Inclusion Criteria:\n\n* Age 18 - 80 years (both inclusive), male or female;\n* Diagnosis of definite, probable, probable laboratory supported or possible ALS as based on the El Escorial and the revised Airlie House diagnostic criteria for ALS;\n* Onset of first symptoms\\* no longer than 24 month... | {
"compound": "FAB122 (edaravone)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00444613 | A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Eisai Co., Ltd. | The purpose of this study is to investigate the efficacy and confirm the safety of E0302 in patients with Amyotrophic Lateral Sclerosis (ALS) by assessing changes in scores of survival rate and functional rating scale. | [
{
"type": "DRUG",
"name": "E0302 (mecobalamin)"
},
{
"type": "DRUG",
"name": "E0302 (mecobalamin)"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2007-04 | https://clinicaltrials.gov/study/NCT00444613 | [
"neuronal_function_and_energy_metabolism"
] | [
{
"facility": "",
"city": "Nagoya",
"state": "Aichi-ken",
"country": "Japan",
"status": "",
"lat": 35.18147,
"lon": 136.90641
},
{
"facility": "",
"city": "Akita",
"state": "Akita",
"country": "Japan",
"status": "",
"lat": 39.71667,
"lon": 140.11667
},
... | {
"criteria": "Inclusion Criteria:\n\n1. Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representa... | {
"compound": "E0302 (mecobalamin)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03488524 | Open Label Extension Study of AMX0035 in Patients With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | This extension study, in which all participants received active treatment (AMX0035), was designed to assess the longer-term safety and therapeutic potential of AMX0035 for participants who have completed the Main Study (AMX3500, also known as CENTAUR). | [
{
"type": "DRUG",
"name": "AMX0035"
}
] | 2018-03-29 | https://clinicaltrials.gov/study/NCT03488524 | [
"TARDBP",
"PFN1"
] | [
{
"facility": "Barrow Neurological Institute-Dignity Health, St Joseph's Hospital and Medical Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California, Irvine",
"cit... | {
"criteria": "Inclusion Criteria:\n\n1. Completion of all visits in the randomized, double blind AMX3500 study. Participants who received tracheostomy or permanent assisted ventilation (PAV) during the course of the main study could enroll in the OLE if they completed all visits in the main study.\n2. Must enroll in... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03202017 | Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS | NA | COMPLETED | INTERVENTIONAL | false | University of Minnesota | The purpose of this study is to investigate the effects of two treatment techniques called Expiratory Muscle Strength Training (EMST) and Lung Volume Recruitment (LVR) on breathing, swallowing, speech, and cough function in persons with mild to moderate ALS. Half of the participants will do EMST alone, and the other ha... | [
{
"type": "PROCEDURE",
"name": "Expiratory Muscle Strength Training (EMST)"
},
{
"type": "PROCEDURE",
"name": "EMST + Lung Volume Recruitment (LVR)"
}
] | 2018-03-01 | https://clinicaltrials.gov/study/NCT03202017 | [] | [
{
"facility": "University of Florida",
"city": "Gainesville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 29.65163,
"lon": -82.32483
},
{
"facility": "University of Minnesota",
"city": "Minneapolis",
"state": "Minnesota",
"country": "United St... | {
"criteria": "Inclusion Criteria:\n\n* ALS defined as possible, laboratory-supported probable, probable, or definite by El Escorial criteria\n* Reduced Maximal Expiratory Pressure (MEP) compared to norms for age and sex\n* Forced Vital Capacity (FVC) \\> 65% predicted\n\nExclusion Criteria:\n\n* Inability to provide... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03154450 | EncoreAnywhere Use in Motor Neurone Disease | NA | COMPLETED | INTERVENTIONAL | false | Sheffield Teaching Hospitals NHS Foundation Trust | Motor neurone disease is a progressive incurable disease causing weakness and paralysis of muscles. Respiratory failure is the most common cause of death in motor neurone disease. Patients with respiratory failure use a machine that supports breathing using a mask and ventilator (non-invasive ventilation: NIV) and usin... | [
{
"type": "DEVICE",
"name": "EncoreAnywhere with data available to review"
},
{
"type": "DEVICE",
"name": "EncoreAnywhere with no data available to review"
}
] | 2016-01-21 | https://clinicaltrials.gov/study/NCT03154450 | [] | [
{
"facility": "Royal Hallamshire Hospital",
"city": "Sheffield",
"state": "South Yorkshire",
"country": "United Kingdom",
"status": "",
"lat": 53.38297,
"lon": -1.4659
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Patients with motor neuron disease diagnosed by a consultant neurologist.\n2. Receiving care from the Sheffield Teaching Hospitals NHS Trust MND clinic\n3. Respiratory failure diagnosed by the clinical team needing to start NIV\n4. Determined to be suitable for and willing to ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01753076 | Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | GlaxoSmithKline | This is a 48-week, randomised, multi-centre, double-blind, placebo-controlled, parallel group investigation of the efficacy and safety of intravenous (IV) ozanezumab (GSK1223249) compared to placebo in subjects with Amyotrophic Lateral Sclerosis (ALS). Following a screening period of up to four weeks, eligible subjects... | [
{
"type": "DRUG",
"name": "Ozanezumab"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2012-12-20 | https://clinicaltrials.gov/study/NCT01753076 | [
"Nogo-A"
] | [
{
"facility": "GSK Investigational Site",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "GSK Investigational Site",
"city": "Grand Rapids",
"state": "Michigan",
"country": "Unit... | {
"criteria": "Inclusion Criteria:\n\n* Patients with diagnosis of familial or sporadic ALS\n* Onset of muscle weakness no more than 30 months before screening visit.\n* Slow Vital Capacity (SVC) of at least 65% predicted for gender, age, ethnicity and height at Screening.\n* If on riluzole, the dose must have been s... | {
"compound": "Ozanezumab",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06681610 | Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study | NA | RECRUITING | INTERVENTIONAL | false | Parc de Salut Mar | The goal of this clinical trial is to assess the efficacy of TPS of the motor cortex on biomarkers and clinical endpoints in patients with ALS. The main questions it aims to answer are:
* Stage 1: Is there a change in the short intracortical inhibition (SICI) of the motor cortex from baseline to week 8?
* Stage 2: Is ... | [
{
"type": "DEVICE",
"name": "Transcranial Pulse Stimulation"
}
] | 2024-10-24 | https://clinicaltrials.gov/study/NCT06681610 | [
"motor_cortex_excitability"
] | [
{
"facility": "Hospital del Mar",
"city": "Barcelona",
"state": "Catalonia",
"country": "Spain",
"status": "RECRUITING",
"lat": 41.38879,
"lon": 2.15899
}
] | +34932 48 30 00 | aleonjorba@psmar.cat | {
"criteria": "Inclusion Criteria:\n\n* Patients with diagnosis of sporadic ALS (definite or clinically probable) as defined by the World Federation of Neurology revised El Escorial criteria\n* SVC of 50% or greater of estimated measure and presence of measurable motor evoked potential\n* 21 to 80 years old and male ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02710110 | Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS) | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | University of Florida | Dysphagia (swallow impairment), dystussia (cough impairment) and respiratory impairment are hallmark features of amyotrophic lateral sclerosis (ALS). These symptoms are the cause of fatal aspiration, malnutrition and respiratory insufficiency that together account for 91.4% of ALS mortality. Unfortunately, treatments t... | [
{
"type": "DEVICE",
"name": "PowerLung trainer"
},
{
"type": "DEVICE",
"name": "Micro Mouth Pressure Meter"
},
{
"type": "PROCEDURE",
"name": "Pulmonary Function Testing"
},
{
"type": "PROCEDURE",
"name": "Videofluoroscopic swallowing study"
},
{
"type": "OTHER",
... | 2016-04 | https://clinicaltrials.gov/study/NCT02710110 | [
"respiratory_function",
"swallowing_dysphagia"
] | [
{
"facility": "UF Health Shands",
"city": "Gainesville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 29.65163,
"lon": -82.32483
}
] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of probable or definite Amyotrophic Lateral Sclerosis (ALS),\n* Amyotrophic Lateral Sclerosis Rating Scale Revised score greater than 34,\n* forced vital capacity greater than 70%,\n* cognition within normal limits as determined by Montreal assessment of cognition sco... | {
"compound": "Capsaicin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07287397 | Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Vector Y Therapeutics | PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS).
Two escalating dose (... | [
{
"type": "GENETIC",
"name": "VTx-002"
},
{
"type": "DRUG",
"name": "Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone"
}
] | 2025-12-19 | https://clinicaltrials.gov/study/NCT07287397 | [
"vtx_002"
] | [
{
"facility": "St Joseph's Hospital and medical Center - Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "NOT_YET_RECRUITING",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California San Diego Medi... | patients@vectorytx.com | patients@vectorytx.com | {
"criteria": "Key Inclusion Criteria:\n\n1. Capable of, and willing to, provide written informed consent and comply with study procedures, including visits to the study site and visit requirements\n2. Male or female ≥ 18 years of age\n3. Has a diagnosis of ALS according to the El Escorial criteria (Brooks, et al., 2... | {
"compound": "VTx-002",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07325591 | Efficacy and Safety of Tazbentetol in ALS Participants | PHASE2, PHASE3 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Spinogenix | The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability. | [
{
"type": "DRUG",
"name": "Tazbentetol"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2026-10-01 | https://clinicaltrials.gov/study/NCT07325591 | [
"tazbentetol"
] | [] | 503 915 1400 | contact@spinogenix.com | {
"criteria": "Inclusion Criteria:\n\n* Age 18-80\n* ALS TRICALS risk score\n* Stable dose of standard of care treatment\n* Contraception use by men or women consistent with local regulations\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Underlying physical or psychological condi... | {
"compound": "Tazbentetol",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03707795 | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | Edward Kasaraskis | By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or deto... | [
{
"type": "DRUG",
"name": "Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days"
}
] | 2017-08-21 | https://clinicaltrials.gov/study/NCT03707795 | [
"FUS",
"oxidative_stress"
] | [
{
"facility": "University of Kentucky Medical Center",
"city": "Lexington",
"state": "Kentucky",
"country": "United States",
"status": "",
"lat": 37.98869,
"lon": -84.47772
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of familial ALS (fALS)\n* Relative of a fALS person and carry the FUS gene\n\nExclusion Criteria:\n\n* Under 20 years or over 80 years of age\n* Cannot tolerate steroids, including betamethasone\n* Are unwilling or unable to attend all scheduled research visits\n* Cur... | {
"compound": "Betamethasone sodium phosphate/betamethasone acetate",
"targeting_mechanism": "Corticosteroid with anti-inflammatory and antioxidant properties targeting oxidative stress implicated in FUS-related ALS pathogenesis.",
"targeting_mechanism_pmid": "34663413",
"animal_results": "unknown",
"animal_r... | ||
NCT00445172 | A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Eisai Co., Ltd. | The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "E0302 (mecobalamin)"
}
] | 2008-02 | https://clinicaltrials.gov/study/NCT00445172 | [
"mecobalamin"
] | [
{
"facility": "",
"city": "Nagoya",
"state": "Aichi-ken",
"country": "Japan",
"status": "",
"lat": 35.18147,
"lon": 136.90641
},
{
"facility": "",
"city": "Aomori",
"state": "Aomori",
"country": "Japan",
"status": "",
"lat": 40.81667,
"lon": 140.73333
},... | {
"criteria": "Inclusion Criteria:\n\n1. Patients who have completed Phase II/III study of E0302 (E0302-J081-761, hereafter referred to as Study 761) except for those patients who discontinued the treatment of Study 761. Completed patients are defined as those who completed the treatment period of Study 761, those on... | {
"compound": "E0302 (mecobalamin)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03296501 | Intraspinal Transplantation of Autologous ADRC in ALS Patients | PHASE1 | UNKNOWN | INTERVENTIONAL | false | Mossakowski Medical Research Centre Polish Academy of Sciences | The goal of our nonrandomized, open label study is to investigate the safety and efficacy of autologous adipose derived mesenchymal regenerative cells (ADRC) transplantation into the individuals with diagnosed amyotrophic lateral sclerosis (ALS). All enrolled patients will have a documented at least 3-months clinical a... | [
{
"type": "BIOLOGICAL",
"name": "Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients"
}
] | 2015-10-13 | https://clinicaltrials.gov/study/NCT03296501 | [
"neurotrophic_factors",
"motor_neuron_degeneration"
] | [
{
"facility": "Medical University of Warsaw",
"city": "Warsaw",
"state": "",
"country": "Poland",
"status": "",
"lat": 52.22977,
"lon": 21.01178
}
] | {
"criteria": "Inclusion Criteria:\n\n* clinically definite or probable ALS according to El Escorial criteria\n* life expectancy of more than 1 year\n* INR ≤2 before liposuction\n* lack of treatment with immune-suppressants and/or corticosteroids within min. 20 days prior to recruitment\n* constant riluzole treatment... | {
"compound": "autologous adipose derived regenerative cells (ADRC)",
"targeting_mechanism": "Stem cells differentiate into support cells such as astrocytes, oligodendrocytes or microglia to produce growth factors, anti-inflammatory cytokines, and provide neuroprotection to degenerating motor neurons.",
"targetin... | ||
NCT02017912 | Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Brainstorm-Cell Therapeutics | This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in patients with ALS .
MSC-NTF cells are a novel cell-therapeutic approach which is expected... | [
{
"type": "BIOLOGICAL",
"name": "Nurown MSC-NTF cells"
},
{
"type": "BIOLOGICAL",
"name": "Placebo"
}
] | 2014-05 | https://clinicaltrials.gov/study/NCT02017912 | [
"neurotrophic_factors",
"motor_neuron_survival"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "UMass Medical School",
"city": "Worcester",
"state": "Massachusetts",
"country": "... | {
"criteria": "Inclusion Criteria\n\n1. Males and females ages 18 to 75 years old, inclusive.\n2. ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.\n3. Disease onset, as defined by first reported occurrence of symptomatic weakness, spasticity, ... | {
"compound": "MSC-NTF cells (autologous neurotrophic factor-secreting mesenchymal stromal cells)",
"targeting_mechanism": "Mesenchymal stromal cells engineered to secrete neurotrophic factors that provide survival signals and neuroprotection to motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results":... | ||
NCT02781454 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Washington | The purpose of this research study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS. The investigators will also determine if there are any signs that the drug may slow down the progression of ALS and reduce... | [
{
"type": "DRUG",
"name": "Mexiletine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2016-10 | https://clinicaltrials.gov/study/NCT02781454 | [
"Sodium channel",
"motor_neuron_electrical_activity"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California, Irvine",
"city": "Orange",
"state": "California",
"country": ... | {
"criteria": "Inclusion Criteria:\n\n1. Sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite ALS as defined by revised El Escorial criteria.\n2. Age 18 years or older.\n3. Symptom onset of weakness or spasticity due to ALS ≤ 60 months prior to Screening Visit.\n4. Slow vital capac... | {
"compound": "Mexiletine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06286475 | A Study of VRG50635 in Healthy Volunteers | PHASE1 | COMPLETED | INTERVENTIONAL | false | Verge Genomics | The primary objectives of this study are to investigate the safety and tolerability of VRG50635 and to determine how VRG50635 is absorbed by the body. | [
{
"type": "DRUG",
"name": "VRG50635"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2024-02-29 | https://clinicaltrials.gov/study/NCT06286475 | [] | [
{
"facility": "Lincoln Celerion Inc.,",
"city": "Lincoln",
"state": "Nebraska",
"country": "United States",
"status": "",
"lat": 40.8,
"lon": -96.66696
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Must be ≥ 19 and ≤ 55 years of age at Screening.\n2. Must be willing and able to voluntarily give written informed consent by signing an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form prior to any study-related procedures bei... | {
"compound": "VRG50635",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07292545 | Video-Based Proprioceptive Exercise Program in ALS | NA | RECRUITING | INTERVENTIONAL | false | Tarsus University | In the project, it was aimed to evaluate the proprioceptive system in the disease, which is still mysterious and therefore has no curative treatment under current conditions, and to examine the effects of the video-based proprioceptive home exercise programme on trunk and limb control and daily life activity as well as... | [
{
"type": "OTHER",
"name": "video based exercise"
}
] | 2025-07-14 | https://clinicaltrials.gov/study/NCT07292545 | [
"proprioceptive_system"
] | [
{
"facility": "Tarsus University",
"city": "Mersin",
"state": "TARSUS",
"country": "Turkey (Türkiye)",
"status": "RECRUITING",
"lat": 36.81196,
"lon": 34.63886
}
] | 03246000033 | fzt_evrim@hotmail.com | {
"criteria": "Inclusion Criteria:Inclusion Criteria:\n\n* ALS patients aged 18-70\n* Those with a definite ALS diagnosis according to the Gold Coast criteria\n* Those who can sit independently\n* Those who have no cognitive problems\n* Those who agree to participate in the study will be included in the study.\n\nExc... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT05797753 | A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Sanofi | This is a Phase 1, cross-over, 2-part study for pharmacokinetic (PK) assessment of SAR443820 when co-administered with cytochrome P450 3A4 (CYP3A4) inhibitors (erythromycin ethyl succinate (EES) in Part A and possibly itraconazole in Part B).
In Part A, the objective is to assess the effects of repeated administration... | [
{
"type": "DRUG",
"name": "SAR443820"
},
{
"type": "DRUG",
"name": "SAR443820"
},
{
"type": "DRUG",
"name": "Erythromycin ethyl succinate"
},
{
"type": "DRUG",
"name": "Itraconazole"
}
] | 2022-02-18 | https://clinicaltrials.gov/study/NCT05797753 | [] | [
{
"facility": "Nucleus Network Site Number : 8400001",
"city": "Saint Paul",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.94441,
"lon": -93.09327
}
] | {
"criteria": "Inclusion Criteria:\n\n* Part A: male or female participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent\n* Part B: male participant only must be 18 to 55 years of age inclusive, at the time of signing the informed consent\n* Body weight between 50.0 and 100.0 kg... | {
"compound": "SAR443820",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03457753 | Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Aquestive Therapeutics | The primary objective of this study is to assess the safety and tolerability, with emphasis on the oral cavity, of ROSF (containing riluzole 50mg) in subjects with amyotrophic lateral sclerosis (ALS) administered twice daily for 12 weeks. Secondary objectives include (1) to record the subject's assessment of any diffic... | [
{
"type": "DRUG",
"name": "Riluzole Oral Soluble Film"
}
] | 2018-03-01 | https://clinicaltrials.gov/study/NCT03457753 | [
"glutamate_excitotoxicity"
] | [
{
"facility": "Texas Neurology, P.A.",
"city": "Dallas",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 32.78306,
"lon": -96.80667
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Male or female subjects, between 18-80 years of age, inclusive.\n2. Subjects having a diagnosis of probable or definite ALS in accordance with the Revisited El-Escorial Criteria.\n3. Subjects must have no known allergy to riluzole or inactive ingredients\\* in ROSF.\n4. Subjec... | {
"compound": "Riluzole Oral Soluble Film",
"targeting_mechanism": "Riluzole blocks glutamatergic neurotransmission by acting as a sodium channel blocker on presynaptic neurons to decrease glutamate release and increase glutamate reuptake, reducing glutamate excitotoxicity.",
"targeting_mechanism_pmid": "37296644... | ||
NCT07204977 | Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | National Institute of Neurological Disorders and Stroke (NINDS) | Background:
Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time. Half of all people with ALS live only 3 to 5 years after diagnosis. Current drug treatments can slow the... | [
{
"type": "DRUG",
"name": "Acamprosate calcium"
}
] | 2026-02-02 | https://clinicaltrials.gov/study/NCT07204977 | [
"C9orf72"
] | [
{
"facility": "National Institutes of Health Clinical Center",
"city": "Bethesda",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 38.98067,
"lon": -77.10026
}
] | {
"criteria": "* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following inclusion criteria:\n\n1. Aged 18 years or older at the time of the screening visit.\n2. Able to provide informed consent and comply with study procedures and availability for the... | {
"compound": "Acamprosate calcium",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03196375 | A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps. | PHASE2 | TERMINATED | INTERVENTIONAL | false | Flex Pharma, Inc. | The COMMEND Study will assess the safety and effectiveness of FLX-787 in men and women with Motor Neuron Disease \[including Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy (PMA)\] experiencing muscle cramps. Participants will be asked to take two study products duri... | [
{
"type": "DRUG",
"name": "FLX-787-ODT (orally disintegrating tablet)"
},
{
"type": "DRUG",
"name": "Placebo ODT"
}
] | 2017-07-28 | https://clinicaltrials.gov/study/NCT03196375 | [] | [
{
"facility": "Honor Health Research Institute",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "Mayo Clinic",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States"... | {
"criteria": "Inclusion Criteria:\n\n* Documented diagnosis of Motor Neuron Disease (MND) \\[including Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy (PMA)\\]\n* Expected survival \\> 6 months\n* Weekly muscle cramping (defined as: a sustained muscle contraction ... | {
"compound": "FLX-787-ODT",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07656714 | HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: a Pilot Trial | NA | COMPLETED | INTERVENTIONAL | false | Hospital Universitario Virgen Macarena | This pilot randomised single-blind trial evaluated whether adding high-frequency chest wall oscillation (HFCWO) via chest vest (ComfortCough II) to mechanical cough assist improves respiratory outcomes and reduces respiratory infections and hospital admissions compared to mechanical cough assist alone in patients with ... | [
{
"type": "DEVICE",
"name": "High-frequency chest wall oscillation (HFCWO) vest"
},
{
"type": "DEVICE",
"name": "Mechanical cough assist"
}
] | 2021-04-15 | https://clinicaltrials.gov/study/NCT07656714 | [] | [
{
"facility": "Hospital Universitario Virgen Macarena",
"city": "Seville",
"state": "Andalusia",
"country": "Spain",
"status": "",
"lat": 37.38283,
"lon": -5.97317
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Confirmed diagnosis of ALS according to the Revised El Escorial criteria\n2. Under follow-up at the Multidisciplinary ALS Unit of Hospital Universitario Virgen Macarena\n3. Age between 18 and 90 years\n4. Peak cough flow less than 270 L/min or forced vital capacity (FVC) less ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05407324 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | RECRUITING | INTERVENTIONAL | false | Corcept Therapeutics | The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Dazucorilant 300 mg"
},
{
"type": "DRUG",
"name": "Dazucorilant 150 mg"
},
{
"type": "OTHER",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Dazucorilant"
}
] | 2022-11-15 | https://clinicaltrials.gov/study/NCT05407324 | [
"Glucocorticoid receptor"
] | [
{
"facility": "062",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "RECRUITING",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "278",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "RECRUI... | (650) 249-9965 | study652@corcept.com | {
"criteria": "Inclusion Criteria:\n\n* Male and female patients ≥18 years of age with sporadic or familial ALS. In Part 1, patients must have a risk of ALS progression characterized by a European Network for the Cure of ALS (ENCALS) risk profile score ≥ -6 and ≤ -3. In Part 2 patients must have a risk of ALS progres... | {
"compound": "Dazucorilant",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02881476 | Therapeutic Treatment of Amyotrophic Lateral Sclerosis | PHASE1 | UNKNOWN | INTERVENTIONAL | false | University of Warmia and Mazury | The goal of this study is to investigate the safety and tolerability of allogeneic Wharton's jelly-derived mesenchymal stem cells administration in the individuals with diagnosed amyotrophic lateral sclerosis. | [
{
"type": "OTHER",
"name": "Biological: Cell-based therapy"
}
] | 2015-11 | https://clinicaltrials.gov/study/NCT02881476 | [
"neuroprotection"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of the ALS disease before the cell transplantation (diagnose established following the El Escorial criteria for definite ALS)\n* good understanding of the protocol and willingness to consent\n* signed informed consent\n* disease duration: up to 2 years\n* FVC \\> 50% ... | {
"compound": "allogeneic Wharton's jelly-derived mesenchymal stem cells",
"targeting_mechanism": "Cell-based therapy that targets multiple disease pathways by supporting motor neuron survival through production of growth factors and anti-inflammatory cytokines.",
"targeting_mechanism_pmid": "34890069",
"animal... | ||
NCT03150290 | Brown Adipose Tissue in ALS | NA | COMPLETED | INTERVENTIONAL | false | Institut National de la Santé Et de la Recherche Médicale, France | Weight loss is a common phenomenon in ALS. During the course of the disease, difficulty in swallowing and mastication can be responsible for a decrease in caloric intake and thus for weight loss. However, significant weight loss can also be observed in patients with no feeding difficulties. About half of ALS patients h... | [
{
"type": "OTHER",
"name": "Indirect Calorimetry."
},
{
"type": "DEVICE",
"name": "18-FDG-PET"
}
] | 2017-10-26 | https://clinicaltrials.gov/study/NCT03150290 | [] | [
{
"facility": "Paris Als Center, Salpetriere Hospital",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "10 ALS patients, fulfilling the following inclusion criteria:\n\n* Aged 18 to 85 (inclusive)\n* Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria\n* With unexplained significant loss of weight of 5 pe... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03792490 | Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | University Medical Center Goettingen | Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder and therapeutic options are limited. The rho kinase (ROCK) inhibitor Fasudil was shown to be neuroprotective, induced axonal regeneration and improved survival and behavioral outcome in models of ALS and other neurodegenerative diseases. Th... | [
{
"type": "DRUG",
"name": "Fasudil"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2019-02-20 | https://clinicaltrials.gov/study/NCT03792490 | [
"ROCK"
] | [
{
"facility": "Centre Hospitalier Universitaire Marseille",
"city": "Marseille",
"state": "",
"country": "France",
"status": "",
"lat": 43.29695,
"lon": 5.38107
},
{
"facility": "Centre Hospitalier Universitaire Montpellier",
"city": "Montpellier",
"state": "",
"count... | {
"criteria": "Inclusion Criteria:\n\n* Probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria\n* Disease duration more than 6 months and less than 24 months (inclusive). Disease onset defined as date of first muscle weakness, exc... | {
"compound": "Fasudil",
"targeting_mechanism": "Rho kinase (ROCK) inhibitor that induces neuroprotection and axonal regeneration.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | PHASE3 | TERMINATED | INTERVENTIONAL | false | Shionogi | To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48: | [
{
"type": "DRUG",
"name": "MT-1186"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2020-11-13 | https://clinicaltrials.gov/study/NCT04569084 | [
"oxidative_stress"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center (SJHMC)",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "HonorHealth Neurology",
"city": "Scottsdale",
"state": "Arizona",
"c... | {
"criteria": "Inclusion Criteria:\n\n1. Subjects must provide a signed and dated informed consent form (ICF) to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study. Subjects must be willing ... | {
"compound": "MT-1186 (oral edaravone)",
"targeting_mechanism": "Antioxidant that reduces oxidative stress and reactive oxygen species.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05370079 | Control Cohort CTRL COH | NA | RECRUITING | INTERVENTIONAL | false | Hospices Civils de Lyon | Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers. | [
{
"type": "BIOLOGICAL",
"name": "Collection of biological sample (blood and/or CSF)"
}
] | 2023-08-08 | https://clinicaltrials.gov/study/NCT05370079 | [] | [
{
"facility": "Hospices Civils de Lyon",
"city": "Bron",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 45.73865,
"lon": 4.91303
}
] | (33) 4 72 35 78 06 | jerome.honnorat@chu-lyon.fr | {
"criteria": "Inclusion Criteria:\n\n* patient with consent\n* patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.\n\nExclusion Criteria:\n\n* ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00403104 | Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Ono Pharmaceutical Co., Ltd. | The purpose of this study is to determine if oral treatment with ONO-2506PO in patients diagnosed with ALS, who have had onset of muscle weakness within 14 months of randomization, could lead to the slowing of decline in respiratory function, functional status, muscle strength, quality of life and survival compared wit... | [
{
"type": "DRUG",
"name": "ONO-2506PO"
},
{
"type": "DRUG",
"name": "ONO-2506PO"
}
] | 2006-11 | https://clinicaltrials.gov/study/NCT00403104 | [
"astrocyte_activation"
] | [
{
"facility": "L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien",
"city": "Vienna",
"state": "",
"country": "Austria",
"status": "",
"lat": 48.20849,
"lon": 16.37208
},
{
"facility": "UCL Saint-Luc",
"city": "Brussels",
"state": ... | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosis of clinically possible, clinically probable laboratory-supported, clinically probable or clinically definite ALS (according to WNF EL Escorial diagnostic criteria, revised according to the Airlie House Conference 1998)\n2. Onset of muscle weakness within 14 months ra... | {
"compound": "ONO-2506PO",
"targeting_mechanism": "ONO-2506PO targets astrocyte activation and dysfunction, modulating glial support for neuronal function in ALS.",
"targeting_mechanism_pmid": "28641533",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_fr... | ||
NCT06169176 | RAPA-501 Therapy of ALS Expanded Access Protocol | Expanded Access | TEMPORARILY_NOT_AVAILABLE | EXPANDED_ACCESS | true | Rapa Therapeutics LLC | RAPA-501-ALS is an Intermediate-Size Expanded Access Trial of RAPA-501 autologous hybrid TREG/Th2 T stem cells in patients living with amyotrophic lateral sclerosis (pwALS). | [
{
"type": "OTHER",
"name": "RAPA-501 Autologous T stem cells"
}
] | https://clinicaltrials.gov/study/NCT06169176 | [
"neuroinflammation"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Mayo Clinic Hospital Phoenix",
"city": "Scottsdale",
"state": "Arizona",
"country": "Un... | {
"criteria": "Inclusion Criteria:\n\n1. Male or female patients ≥ 18 years of age.\n2. Patients with sporadic or familial ALS diagnosed as laboratory-supported possible, probable, or definite according to World Federation of Neurology El Escorial Criteria.\n3. Pulmonary slow vital capacity (SVC) \\< 50% of predicted... | {
"compound": "RAPA-501 autologous hybrid TREG/Th2 T stem cells",
"targeting_mechanism": "RAPA-501 modulates neuroinflammation through immunotherapy targeting regulatory T cells and Th2 responses to mitigate motor neuron degeneration in ALS.",
"targeting_mechanism_pmid": "35303907",
"animal_results": "ASC-Exoso... | |||
NCT02450552 | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | PHASE2 | COMPLETED | INTERVENTIONAL | false | Brian Wainger | This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks. | [
{
"type": "DRUG",
"name": "Ezogabine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2015-06 | https://clinicaltrials.gov/study/NCT02450552 | [
"KCNQ channels"
] | [
{
"facility": "Barrow Neuological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai",
"city": "Los Angeles",
"state": "California",
"country": "United States",... | {
"criteria": "ALS Subject Inclusion Criteria:\n\n* Male or female, aged 18 to 80.\n* Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.\n* Slow vital capacity (SVC) measure ≥ 50% of predicted for gender, height and age at t... | {
"compound": "Ezogabine (Retigabine)",
"targeting_mechanism": "Ezogabine is a potassium channel opener that enhances motor neuron excitability and activity in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid... | ||
NCT01984814 | Stem Cell Therapy for Amyotrophic Lateral Sclerosis | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Neurogen Brain and Spine Institute | The effect of autologous bone marrow mononuclear cells on duration of survival in Amyotrophic Lateral Sclerosis patients. | [
{
"type": "BIOLOGICAL",
"name": "Stem cell"
}
] | 2008-12 | https://clinicaltrials.gov/study/NCT01984814 | [
"neuroprotection"
] | [
{
"facility": "Neurogen brain and spine institute",
"city": "Mumbai",
"state": "Maharashtra",
"country": "India",
"status": "",
"lat": 19.07283,
"lon": 72.88261
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients with the diagnoses of definite amyotrophic lateral sclerosis.\n* Clear information about date of onset of symptoms, documented contact information and follow up information\n\nExclusion Criteria:\n\n* Patients with diagnoses of Progressive Lateral sclerosis, Progressiv... | {
"compound": "Autologous bone marrow mononuclear cells",
"targeting_mechanism": "Stem cell transplantation provides neuroprotection and motor neuron support through secretion of trophic factors and modulation of inflammatory responses in ALS.",
"targeting_mechanism_pmid": "36064599",
"animal_results": "unknown... | ||
NCT02383654 | Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | China Medical University Hospital | The purpose of the study is to determine the safety and possible effectiveness of Autologous Adipose-Tissue Derived Stem Cells treatment in a Amyotrophic Lateral Sclerosis(ALS) patient. | [
{
"type": "PROCEDURE",
"name": "Autologous Adipose-Tissue Derived Stem Cells"
}
] | 2015-01 | https://clinicaltrials.gov/study/NCT02383654 | [
"neuroprotection"
] | [
{
"facility": "China Medical University Beigang Hospital",
"city": "Beigang",
"state": "Yunlin",
"country": "Taiwan",
"status": "",
"lat": 23.5701,
"lon": 120.30162
}
] | {
"criteria": "Compassionate Treatment\n\nThe number of participants for a person.\n\nThe patients (Guo XX) of 28% of lung function assessment (normal lung function was greater than 80%), the daily life of motor function score was 17 points (normal function score of 40 points).",
"sex": "MALE",
"min_age": "35 Yea... | {
"compound": "Autologous Adipose-Tissue Derived Stem Cells",
"targeting_mechanism": "Adipose-derived stem cells differentiate into supportive cells (astrocytes, oligodendrocytes, microglia) that produce growth factors and anti-inflammatory cytokines to protect degenerating motor neurons.",
"targeting_mechanism_p... | ||
NCT06556394 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation | PHASE1 | RECRUITING | INTERVENTIONAL | false | Ractigen Therapeutics. | This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects with Amyotrophic Lateral Sclerosis (ALS) with Superoxide Dismutase Type 1 (SOD1) Gene Mutation | [
{
"type": "DRUG",
"name": "RAG-17"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2024-12-24 | https://clinicaltrials.gov/study/NCT06556394 | [
"SOD1"
] | [
{
"facility": "Beijing Tiantan Hospital",
"city": "Beijing",
"state": "",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
},
{
"facility": "West China Hospital of Sichuan University",
"city": "Chengdu",
"state": "",
"country": "China",
... | +86 18051622388 | lilc@ractigen.com | {
"criteria": "Inclusion Criteria:\n\n1. Voluntarily consents to participate in this study and provides written informed consent prior to the start of any study specific procedures.\n2. ≥ 18 years of age at the time of informed consent.\n3. Diagnosis of possible, laboratory supported probable, probable, or definite A... | {
"compound": "RAG-17",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT01492686 | Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis | PHASE3 | COMPLETED | INTERVENTIONAL | false | Shionogi | The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is als... | [
{
"type": "DRUG",
"name": "MCI-186"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "MCI-186 in open label phase"
}
] | 2011-12-31 | https://clinicaltrials.gov/study/NCT01492686 | [
"oxidative_stress"
] | [
{
"facility": "",
"city": "Osaka",
"state": "",
"country": "Japan",
"status": "",
"lat": 34.69379,
"lon": 135.50107
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients whose conditions are defined as \"definite ALS\"or \"probable ALS\"diagnostic criteria El Escorial and revised Airlie House.\n* Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life.\n* Patients of less than 2 yea... | {
"compound": "MCI-186",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02880033 | Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Lille | Peripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism... | [
{
"type": "DRUG",
"name": "deferiprone"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2011-02 | https://clinicaltrials.gov/study/NCT02880033 | [
"oxidative_stress",
"iron_metabolism"
] | [
{
"facility": "Hôpital Roger Salengro, CHRU de Lille",
"city": "Lille",
"state": "",
"country": "France",
"status": "",
"lat": 50.63391,
"lon": 3.05512
}
] | {
"criteria": "Inclusion Criteria:\n\n* Parkinson's disease according to Movement Disorders Society criteria\n* Amyotrophic Lateral Sclerosis according to El escorial criteria\n* Age and sex matched healthy controls\n\nExclusion Criteria:\n\n* Severe comorbidities (cancer, other degenerative diseases, hemopathy, infl... | {
"compound": "deferiprone",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06551649 | Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation | NA | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Neurodegenerative diseases are debilitating conditions characterized by chronic inflammation, leading to dysfunction of both the non-neuronal cellular components of the central nervous system and peripheral blood immune cells. Thus, it is crucial to develop an innovative therapeutic strategy that not only effectively c... | [
{
"type": "OTHER",
"name": "Venous blood draw and skin biopsy"
}
] | 2025-01-17 | https://clinicaltrials.gov/study/NCT06551649 | [
"neuroinflammation"
] | [
{
"facility": "Fondazione Policlinico Universitario A. Gemelli IRCCS",
"city": "Roma",
"state": "",
"country": "Italy",
"status": "",
"lat": 44.99364,
"lon": 11.10642
},
{
"facility": "Fondazione Policlinico Universitario Agostino Gemelli IRCCS",
"city": "Rome",
"state": ... | {
"criteria": "Inclusion Criteria:\n\n* For patients with amyotrophic lateral sclerosis (ALS): aged between 50 and 60 years and similar age of onset and duration of the disease.\n* For patients with multiple sclerosis (MS): with recently confirmed diagnosis of MS, aged between 20 and 50 years and considering the male... | {
"compound": "unknown",
"targeting_mechanism": "Reducing neuroinflammation and modulating immune responses to protect against neurodegeneration.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": "... | ||
NCT01536249 | Dexpramipexole and Cimetidine Drug Drug Interaction (DDI) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | This study will assess the effect of cimetidine on the pharmacokinetics (PK) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine. Additionally, this study will explore the influence of genetic variation on the PK of dexpramipexole when ... | [
{
"type": "DRUG",
"name": "Dexpramipexole"
},
{
"type": "DRUG",
"name": "Cimetidine plus Dexpramipexole"
}
] | 2012-03 | https://clinicaltrials.gov/study/NCT01536249 | [
"mitochondrial_complex_i"
] | [
{
"facility": "Research Site",
"city": "Overland Park",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 38.98223,
"lon": -94.67079
}
] | {
"criteria": "Inclusion Criteria:\n\n* Subjects who, in the opinion of the Investigator, are healthy as determined by medical history, physical examination, and 12 lead ECG\n* Adult males/females aged 18 to 55 years inclusive\n* Male and female subjects of childbearing potential must practice effective contraception... | {
"compound": "Dexpramipexole",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04745299 | Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Corestemchemon, Inc. | ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment. | [
{
"type": "BIOLOGICAL",
"name": "Lenzumestrocel"
},
{
"type": "DRUG",
"name": "Riluzole"
},
{
"type": "DRUG",
"name": "Placebo Comparator"
}
] | 2021-02-24 | https://clinicaltrials.gov/study/NCT04745299 | [
"neuroinflammation"
] | [
{
"facility": "Pusan National University Yangsan Hospital",
"city": "Yangsan",
"state": "Kyungsangnam-do",
"country": "South Korea",
"status": "",
"lat": 35.34199,
"lon": 129.03358
},
{
"facility": "Hanyang university hospital",
"city": "Seoul",
"state": "Seoul",
"cou... | {
"criteria": "\\[Inclusion Criteria\\]\n\n1. Subjects who show both upper motor neuron signs and lower motor neuron signs at the same time in neurological tests.\n2. Among subjects diagnosed with familial or sporadic ALS, subjects falling into clinically definite ALS, probable ALS and probable ALS-lab supported acco... | {
"compound": "Lenzumestrocel",
"targeting_mechanism": "Mesenchymal stromal cell therapy that secretes neurotrophic factors and anti-inflammatory cytokines to support degenerating motor neurons.",
"targeting_mechanism_pmid": "34890069",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_fro... | ||
NCT06910384 | A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | New England Cell Therapeutics, Inc. | This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis. | [
{
"type": "BIOLOGICAL",
"name": "STR04"
}
] | 2025-08-12 | https://clinicaltrials.gov/study/NCT06910384 | [] | [
{
"facility": "National Neuromuscular Research Institute",
"city": "Austin",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 30.26715,
"lon": -97.74306
}
] | {
"criteria": "Inclusion:\n\n* \"Definite\" or \"Probable\" ALS according to the Revised El Escorial criteria (Airlie House)\n* ALS severity grade 1 or 2 according to the Japan ALS severity classification.\n* ALSFRS-R scores of 2 or more for all items, with scores of 4 for all breathing- related items (i.e., dyspnea,... | {
"compound": "STR04",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06215755 | A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | TERMINATED | INTERVENTIONAL | false | Verge Genomics | The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS. | [
{
"type": "DRUG",
"name": "VRG50635"
}
] | 2024-01-15 | https://clinicaltrials.gov/study/NCT06215755 | [] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "Flemish Brabant",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Stan Cassidy Centre for Rehabilitation (Horizon NB)",
"city": "Montreal",
"state": "Quebec",
"country": "Cana... | {
"criteria": "Inclusion Criteria:\n\n1. Provide written informed consent and be willing and able to comply with the requirements of the study protocol.\n2. Must be ≥ 18 and ≤ 75 years of age at the time of signing the informed consent form (ICF).\n3. Have a diagnosis of ALS according to the Gold Coast Diagnostic Cri... | {
"compound": "VRG50635",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06881979 | High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project | NA | RECRUITING | INTERVENTIONAL | false | Istituti Clinici Scientifici Maugeri SpA | The primary objective is to demonstrate, in a population of chronic neuromuscular disease the non-inferiority of a rehabilitation treatment integrated with robotic and/or technological devices compared to traditional rehabilitation treatment in the level of fatigue.
The main question it aims to answer is:
Are high-te... | [
{
"type": "DEVICE",
"name": "High-tech rehabilitative treatment"
},
{
"type": "OTHER",
"name": "Rehabilitation"
}
] | 2025-04-28 | https://clinicaltrials.gov/study/NCT06881979 | [] | [
{
"facility": "IRCCS Azienda Ospedaliera Universitaria San Martino - Genova",
"city": "Genova",
"state": "",
"country": "Italy",
"status": "NOT_YET_RECRUITING",
"lat": 45.21604,
"lon": 11.87211
},
{
"facility": "Istituti Clinici Scientifici Maugeri IRCCS, Milan Institute",
"c... | +39 0250725266 | christian.lunetta@icsmaugeri.it | {
"criteria": "Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of chronic neuromuscular diseases (e.g. ALS, CIDP, CMT)\n* Patient able to walk independently or with assistance\n* Patients capable of understanding and adhering to the study protocol.\n* Patients who have provided informed consent to partic... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT05498883 | Quality of Life Evaluation with the SRI Questionnaire of ALS Patient with Non-invasive Ventilation | NA | COMPLETED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | This study aims to measure the quality of life of ALS patients by the SRI questionnaire, in two distinct patient groups : Patient requiring initiation of NIV, and patients 24 hours dependent on NIV
This study also seeks to assess the quality of life of the caregivers with the Zarit Burden interview in those two popula... | [
{
"type": "OTHER",
"name": "Score completion"
}
] | 2022-09-13 | https://clinicaltrials.gov/study/NCT05498883 | [] | [
{
"facility": "Pneumology departement, Pitié-Salpêtrière hospital, GHU APHP-Sorbonne Université",
"city": "Paris",
"state": "Paris",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion Criteria:\n\nPatients :\n\n* 18 years or more\n* Patient followed for ALS probable or certain with Awaji criteria\n* group 1 : severe chronic respiratory failure, with a decision by the attending physician to start NIV\n* group 2 : complete dependence on NIV\n\nCaregivers :\n\n* 18 years or m... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03095989 | An Online Mindfulness Intervention for People With ALS and Their Caregivers | NA | COMPLETED | INTERVENTIONAL | false | Harvard University | The psychological impact of ALS on both patients and caregivers is high and affects their quality of life (QOL). However, there is minimal research about psychological interventions to improve QOL in the ALS scientific literature.
Recent advances in clinical treatments aimed at improving the health of people with chro... | [
{
"type": "BEHAVIORAL",
"name": "Mindfulness"
}
] | 2015-01 | https://clinicaltrials.gov/study/NCT03095989 | [] | [
{
"facility": "Penn State Hershey Medical Center",
"city": "Hershey",
"state": "Pennsylvania",
"country": "United States",
"status": "",
"lat": 40.28592,
"lon": -76.65025
}
] | {
"criteria": "Inclusion Criteria:\n\nInclusion Criteria for ALS Subjects:\n\n* Definite, probable, probable laboratory-supported, or possible ALS by revised El-Escorial criteria (Brooks, Miller, Swash, \\& Munsat, 2000).\n* Must have the physical ability, with or without adaptive devices, to use a computer and acces... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06453668 | A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients | PHASE1 | TERMINATED | INTERVENTIONAL | false | ITB-Med LLC | The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients. | [
{
"type": "BIOLOGICAL",
"name": "TCD601"
}
] | 2024-04-16 | https://clinicaltrials.gov/study/NCT06453668 | [
"cd4_t_cells"
] | [
{
"facility": "Skåne University Hospital Malmö",
"city": "Malmö",
"state": "",
"country": "Sweden",
"status": "",
"lat": 55.60587,
"lon": 13.00073
},
{
"facility": "Studieenheten Akademiskt Specialistcentrum",
"city": "Stockholm",
"state": "",
"country": "Sweden",
... | {
"criteria": "Key Inclusion Criteria:\n\n* Male or female patients ≥ 18 to 80 years of age.\n* Diagnosis of ALS by revised El Escorial Criteria, at study entry within 24 months of first symptoms.\n* Patients on existing ALS treatment must have been on a stable dose for 28 days.\n\nKey Exclusion Criteria:\n\n* Patien... | {
"compound": "TCD601",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04220190 | RAPA-501 Therapy for ALS | PHASE2, PHASE3 | RECRUITING | INTERVENTIONAL | false | Rapa Therapeutics LLC | RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS). | [
{
"type": "BIOLOGICAL",
"name": "RAPA-501 Autologous T stem cells"
}
] | 2025-01-02 | https://clinicaltrials.gov/study/NCT04220190 | [
"neuroinflammation"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "RECRUITING",
"lat": 42.35843,
"lon": -71.05977
}
] | (301) 518-3104 | dan@rapatherapeutics.com | {
"criteria": "Inclusion Criteria:\n\n1. Male or female patients ≥ 18 years of age.\n2. Patients with sporadic or familial amyotrophic lateral sclerosis (ALS) diagnosed as laboratory-supported possible, probable, or definite according to World Federation of Neurology El Escorial Criteria.\n3. . Less than or equal to ... | {
"compound": "RAPA-501",
"targeting_mechanism": "RAPA-501 is an autologous hybrid TREG/Th2 cell therapy targeting neuroinflammation in ALS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00673140 | Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | UNKNOWN | INTERVENTIONAL | false | GAAD Medical Research Institute Inc. | Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.
This study will investigate t... | [
{
"type": "RADIATION",
"name": "Far Infrared Radiation (5μm to 20μm wavelength)"
},
{
"type": "RADIATION",
"name": "Far infrared radiation"
}
] | 2008-05 | https://clinicaltrials.gov/study/NCT00673140 | [] | [
{
"facility": "The Centre for Incurable Diseases",
"city": "Toronto",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 43.70643,
"lon": -79.39864
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients with ALS\n\nExclusion Criteria:\n\n* None",
"sex": "ALL",
"min_age": "",
"max_age": "",
"healthy_volunteers": false,
"std_ages": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
} | {
"compound": "Far Infrared Radiation",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04254913 | Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy | PHASE1 | COMPLETED | INTERVENTIONAL | false | Shionogi | To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Amyotrophic Lateral Sclerosis Patients with gastrostomy | [
{
"type": "DRUG",
"name": "MT-1186"
}
] | 2020-01-24 | https://clinicaltrials.gov/study/NCT04254913 | [
"oxidative_stress"
] | [
{
"facility": "Investigational site",
"city": "Chiba",
"state": "",
"country": "Japan",
"status": "",
"lat": 35.6,
"lon": 140.11667
}
] | {
"criteria": "Inclusion Criteria:\n\nThe key criteria are listed below.\n\n* Patients aged between 20 and 80 years at the time of informed consent\n* Japanese patients\n* Among patients with ALS, those \"Clinically definite ALS,\" \"Clinically probable ALS\" or \"Clinically probable-laboratory-supported ALS\" accord... | {
"compound": "MT-1186 (edaravone oral suspension)",
"targeting_mechanism": "Edaravone reduces oxidative stress by scavenging reactive oxygen species (ROS) and acting as an antioxidant.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unkn... | ||
NCT07298486 | Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS | NA | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | Nova Southeastern University | The goal of this clinical trial is to determine the impact of robotic glove use on quality of life, grip strength and fine motor control in participants with Amyotrophic Lateral Sclerosis (ALS). This will provide valuable insights into how an assistive technology intervention can influence functional ability in daily t... | [
{
"type": "DEVICE",
"name": "Robotic Glove Use"
}
] | 2026-02-09 | https://clinicaltrials.gov/study/NCT07298486 | [] | [
{
"facility": "Nova Southeastern University, David and Cathy Husman Neuroscience Institute",
"city": "Davie",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 26.06287,
"lon": -80.2331
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of clinically possible, probable or definite amyotrophic lateral sclerosis by the treating neurologist\n* Have a caregiver that is willing and present to assist with application of robotic glove\n* Reports fine motor deficits or grip strength deficits in at least 1 ha... | {
"compound": "unknown",
"targeting_mechanism": "Robotic glove provides mechanical assistance to restore arm function and improve grip strength through wearable technology.",
"targeting_mechanism_pmid": "36724237",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
... | ||
NCT04245709 | Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Dwight Koeberl, M.D., Ph.D. | The purpose of this study is to assess the safety and tolerability of clenbuterol (taken by mouth) in subjects with ALS (amyotrophic lateral sclerosis) and to assess the effectiveness of clenbuterol with regard to motor function in subjects with ALS. Subjects will be in this study approximately 24 weeks. The study drug... | [
{
"type": "DRUG",
"name": "Clenbuterol"
}
] | 2020-02-10 | https://clinicaltrials.gov/study/NCT04245709 | [
"Beta-2 adrenergic receptor"
] | [
{
"facility": "Duke University Medical center",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.99403,
"lon": -78.89862
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of possible or more definite ALS according to the El Escorial criteria\n* FVC \\>50% of predicted for age, height and gender.\n* At least four of 12 ALSFRS-R questions scored as 2 or 3 at screening.\n* Diminished but measurable grip strength (1) in at least one hand (... | {
"compound": "Clenbuterol",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01504009 | Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | University of Southern Denmark | Patients with neuropathic diseases are experiencing increasing muscle weakness, loss of muscle strength and functional abilities during their illness. In healthy people, regular exercise is the best way to maintain or improve muscle strength, endurance and general health status and thereby maintain functioning abilitie... | [
{
"type": "OTHER",
"name": "Muscle training"
}
] | 2011-05 | https://clinicaltrials.gov/study/NCT01504009 | [] | [
{
"facility": "Department of Clinical Research, Odense University Hospital, University of Southern Denmark",
"city": "Odense C",
"state": "Fyn",
"country": "Denmark",
"status": "",
"lat": 55.40841,
"lon": 10.39538
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosed with Amyotrophic lateral sclerosis (ALS)\n\nExclusion Criteria:\n\n* Late stage ALS",
"sex": "ALL",
"min_age": "",
"max_age": "",
"healthy_volunteers": false,
"std_ages": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
} | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Swim training modulates skeletal muscle energy metabolism and ameliorates reduction in grip strength in SOD1G93A mice.",
"animal_results_pmid": "30634386",
"repurposed_from": "not repurposed",
"re... | ||
NCT00847847 | Neuromuscular Transmission in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Consistent data suggest that neuromuscular transmission is impaired in ALS patients. Neuromuscular junctions dysfunction may appear very early in the disease, as shown by data in animal models. The pathogenesis of this neuromuscular transmission impairment is unknown. Nogo A isoform, a possible marker of the disease ov... | [
{
"type": "PROCEDURE",
"name": "Anconeus Muscle biopsy"
}
] | 2009-03 | https://clinicaltrials.gov/study/NCT00847847 | [
"neuromuscular_transmission",
"NogoA"
] | [
{
"facility": "Bruneteau Gaelle",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "1. ALS patients:\n\n Inclusion criteria :\n * Aged 18 to 75 (inclusive)\n * Possible, probable (clinically or laboratory) or definite ALS according to the revised El Escorial criteria\n * Duration of the disease of less then 12 months\n * Willing and able to provide a written informed consent... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "In SOD1G93A mouse models, neuromuscular junction (NMJ) denervation and distal axonal degeneration occur prior to symptom onset, indicating early NMJ dysfunction in ALS pathogenesis.",
"animal_results_... | ||
NCT07618585 | Safety and Efficacy of Intrathecal NTF001 Injection in ALS | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Ruijin Hospital | This is a single-arm, open-label, early-phase clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of intrathecal NTF001 injection, an AAV-mediated human neuron-derived neurotrophic factor gene therapy, in patients with amyotrophic lateral sclerosis (ALS).
12 patients with ALS will be... | [
{
"type": "GENETIC",
"name": "NTF001 Injection"
}
] | 2026-04-01 | https://clinicaltrials.gov/study/NCT07618585 | [
"Neurotrophic factor"
] | [
{
"facility": "Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",
"city": "Shanghai",
"state": "Shanghai Municipality",
"country": "China",
"status": "",
"lat": 31.22222,
"lon": 121.45806
}
] | {
"criteria": "Inclusion Criteria:\n\n* Voluntarily participate in this study and sign the informed consent form.\n* Agree to comply with study procedures and cooperate with all study-related assessments throughout the study.\n* Male or female patients aged 18 to 65 years.\n* Meet the diagnostic and exclusion criteri... | {
"compound": "NTF001 Injection",
"targeting_mechanism": "AAV-mediated delivery of human neuron-derived neurotrophic factor gene therapy to provide neuroprotection and motor neuron support.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repu... | ||
NCT07095712 | Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP. | [
{
"type": "DRUG",
"name": "nL-TARD-001"
}
] | 2024-11-25 | https://clinicaltrials.gov/study/NCT07095712 | [
"TARDBP"
] | [
{
"facility": "Columbia University, Irving Medical Center",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
},
{
"facility": "Houston Methodist",
"city": "Houston",
"state": "Texas",
"country": "Unit... | {
"criteria": "Inclusion Criteria:\n\n* Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s)\n* Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to parti... | {
"compound": "nL-TARD-001",
"targeting_mechanism": "Personalized antisense oligonucleotide designed to target a pathogenic TARDBP variant and reduce TDP-43 protein expression or toxicity.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repur... | ||
NCT05882695 | Study of SPG302 in Healthy Volunteers and ALS Participants | PHASE1 | COMPLETED | INTERVENTIONAL | false | Spinogenix | The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants | [
{
"type": "DRUG",
"name": "SPG302"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2023-07-03 | https://clinicaltrials.gov/study/NCT05882695 | [
"spg302"
] | [
{
"facility": "Macquarie University",
"city": "North Ryde",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.79677,
"lon": 151.12436
},
{
"facility": "Royal Brisbane and Women's Hospital",
"city": "Herston",
"state": "Queensland",
"country"... | {
"criteria": "Inclusion Criteria:\n\n* Age 18-55\n* Must be in good health with no significant medical history\n* Clinical laboratory values within normal range or \\< 1.2 times ULN\n* BMI 18-32 (inclusive)\n* Contraceptive use by men or women consistent with local regulations\n* Able and willing to provide written ... | {
"compound": "SPG302",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05039099 | A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | AL-S Pharma | The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS. | [
{
"type": "DRUG",
"name": "AP-101"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-09-02 | https://clinicaltrials.gov/study/NCT05039099 | [
"ap_101"
] | [
{
"facility": "UC San Diego, ACTRI",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Department of Neurology, University Hospitals",
"city": "Leuven",
"state": "",
"country": "Bel... | {
"criteria": "Inclusion Criteria:\n\n* All participants must adhere to contraception restrictions\n* Female participants of childbearing potential must adhere to contraception restrictions\n* Have possible, clinically probable, clinically probable-laboratory supported or definite familial or sporadic ALS in accordan... | {
"compound": "AP-101",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05747937 | Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS | NA | RECRUITING | INTERVENTIONAL | false | Istituti Clinici Scientifici Maugeri SpA | The goal of this interventional non-pharmacological study is to evaluate, using a multimodal approach, the progression of autonomic and sensory involvement in in amyotrophic lateral sclerosis (ALS) patients enrolled within 18 months from motor onset and its relationship with the progression of overall clinical disabili... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "Skin biopsy"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Cardiovascular Reflexes testing"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms"
},
{
"t... | 2021-05-15 | https://clinicaltrials.gov/study/NCT05747937 | [] | [
{
"facility": "ICS Maugeri - IRCCS of Telese Terme",
"city": "Telese Terme",
"state": "Benevento",
"country": "Italy",
"status": "RECRUITING",
"lat": 41.21752,
"lon": 14.52681
},
{
"facility": "Department of Neurosciences, Reproductive Sciences and Odontostomatology, University o... | +390824909257 | maria.nolano@icsmaugeri.it | {
"criteria": "Inclusion Criteria:\n\n* ALS patients will be recruited within 18 months from the motor symptoms onset\n\nExclusion Criteria:\n\n* glucose intolerance or conditions potentially affecting the peripheral nervous system",
"sex": "ALL",
"min_age": "18 Years",
"max_age": "",
"healthy_volunteers": tr... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.